WO2015034051A1 - Bisoprolol-containing adhesive patch and package of same - Google Patents

Bisoprolol-containing adhesive patch and package of same Download PDF

Info

Publication number
WO2015034051A1
WO2015034051A1 PCT/JP2014/073505 JP2014073505W WO2015034051A1 WO 2015034051 A1 WO2015034051 A1 WO 2015034051A1 JP 2014073505 W JP2014073505 W JP 2014073505W WO 2015034051 A1 WO2015034051 A1 WO 2015034051A1
Authority
WO
WIPO (PCT)
Prior art keywords
bisoprolol
pressure
sensitive adhesive
adhesive layer
patch preparation
Prior art date
Application number
PCT/JP2014/073505
Other languages
French (fr)
Japanese (ja)
Inventor
準 石倉
和宏 青柳
智 雨山
直子 漆原
智也 田中
中村 哲也
Original Assignee
日東電工株式会社
トーアエイヨー株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日東電工株式会社, トーアエイヨー株式会社 filed Critical 日東電工株式会社
Priority to CN201480048897.3A priority Critical patent/CN105517543A/en
Priority to KR1020167005441A priority patent/KR20160049532A/en
Publication of WO2015034051A1 publication Critical patent/WO2015034051A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A61J1/10Bag-type containers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61JCONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/14Details; Accessories therefor
    • A61J1/16Holders for containers

Definitions

  • the present invention relates to a patch preparation containing bisoprolol and a package thereof.
  • a patch preparation in which an adhesive sheet containing the drug is applied to the skin has been adopted.
  • an adhesive layer containing a transdermally absorbable drug is laminated on one side of a plastic support such as polyester or polyethylene, and the exposed surface of the adhesive layer is a release liner. It is covered.
  • a patch preparation is individually packaged with a packaging material that is impermeable to moisture in order to prevent volatilization of contained transdermal drug and the influence of humidity.
  • Bisoprolol a highly selective sympathetic ⁇ 1 receptor antagonist ( ⁇ -blocker), is used to improve essential hypertension, angina pectoris, and arrhythmias, and its fumarate is administered orally as a tablet. ing.
  • ⁇ -blocker highly selective sympathetic ⁇ 1 receptor antagonist
  • Patent Document 1 discloses that the patch preparation is contained in a packaging bag in order to suppress the hydrolysis reaction of bisoprolol and improve its storage stability, and at 25 ° C. inside the packaging bag.
  • a packaging bag containing a patch preparation in which the relative humidity is maintained at 25% or less is disclosed.
  • the packaging bag requires a desiccant, is bulky when a package is formed, and is inconvenient to carry and use.
  • Patent Document 2 discloses a patch preparation in which the moisture content of the pressure-sensitive adhesive layer is 1,000 ppm to 8,000 ppm for the purpose of preventing the pressure-sensitive adhesive layer from being colored and suppressing the degradation of donepezil release. ing.
  • the above-mentioned patent document does not suggest improvement of the temporal stability of bisoprolol contained in the patch preparation, nor does it suggest any possibility of application to the bisoprolol-containing patch preparation.
  • the inventors have found that the stability of bisoprolol over time has a significant correlation with the moisture content.
  • the present inventors have found that by controlling the water content of the pressure-sensitive adhesive layer appropriately, the hydrolysis reaction over time of bisoprolol can be suppressed without using a desiccant when packaging a bisoprolol-containing patch preparation. It came to do.
  • the present invention is as follows.
  • a bisoprolol-containing patch preparation comprising a support and a pressure-sensitive adhesive layer containing bisoprolol formed on at least one surface thereof, wherein the water content of the pressure-sensitive adhesive layer is 10,000 ppm or less.
  • the moisture-permeable bag is a packaging material in which an acrylonitrile-based resin layer and a moisture-impermeable layer are laminated, and the acrylonitrile-based resin layer is positioned on the proximal side of the bisoprolol-containing patch preparation.
  • the package according to (5) which is hermetically sealed.
  • the time-dependent hydrolysis of bisoprolol in the pressure-sensitive adhesive layer can be suppressed without using a desiccant when packaging a bisoprolol-containing patch preparation, so that the stability and reliability with time are improved.
  • a bisoprolol-containing patch preparation can be realized, and a package of a bisoprolol-containing patch preparation excellent in usability and portability can be provided. This increases the patient's quality of life (QOL) and economics.
  • the bisoprolol-containing patch preparation of the present invention has a support and a pressure-sensitive adhesive layer containing bisoprolol formed on at least one side of the support.
  • the bisoprolol-containing patch preparation of the present invention may be referred to as “the patch preparation of the present invention” or simply “the patch preparation”.
  • the support that can be used in the present invention is not particularly limited, but a material that is substantially impermeable to drugs or the like, that is, a component contained in an adhesive layer such as an active ingredient bisoprolol or an additive. Those that pass through the support and are lost from the back are not preferred.
  • polyester, polyamide, polyvinylidene chloride, polyethylene, polypropylene, polyvinyl chloride, ethylene-ethyl acrylate copolymer, polytetrafluoroethylene, ionomer resin, a single film such as a metal foil, or a laminate thereof A film or the like can be used.
  • the thickness of the support is usually 5 ⁇ m to 500 ⁇ m, preferably 10 ⁇ m to 200 ⁇ m.
  • the support in order to improve the adhesion (throwing property) between the support and the pressure-sensitive adhesive layer, is preferably a laminated film of a nonporous plastic film made of the above material and a porous film. . In this case, it is desirable to form the pressure-sensitive adhesive layer on the porous film side.
  • porous film one that improves anchoring property with the pressure-sensitive adhesive layer is adopted, and specifically, paper, woven fabric, non-woven fabric, knitted fabric, a mechanically perforated sheet, and the like are mentioned. It is done. Among these, paper, woven fabric, and non-woven fabric are particularly preferable from the viewpoint of handleability and the like.
  • a porous film having a thickness in the range of 10 ⁇ m to 200 ⁇ m is preferably used from the viewpoints of improvement of anchoring property, flexibility of the whole patch preparation, sticking operability, and the like.
  • a thin patch preparation such as a plaster type or an adhesive tape type
  • one having a thickness in the range of 10 ⁇ m to 100 ⁇ m is preferably employed.
  • the basis weight thereof is preferably 5 g / m 2 to 30 g / m 2 , more preferably 6 g / m 2 to 15 g / m 2 .
  • the most preferable support is a non-woven fabric made of a polyester film (preferably polyethylene terephthalate film) having a thickness of 1.5 ⁇ m to 6 ⁇ m and a polyester (preferably polyethylene terephthalate) having a basis weight of 6 g / m 2 to 15 g / m 2. And a laminated film.
  • the pressure-sensitive adhesive layer contains bisoprolol.
  • Bisoprolol is already marketed as an oral preparation, and in the case of a tablet, it is contained in the form of a salt such as bisoprolol fumarate.
  • bisoprolol can be contained in the adhesive layer not only in the free form (free base) but also in the form of a pharmaceutically acceptable salt. From the viewpoint of skin permeability, it is desirable that bisoprolol is contained in the pressure-sensitive adhesive layer as a free body.
  • the content of bisoprolol in the patch preparation of the present invention is preferably 0.5% to 40% by weight and more preferably 0.5% to 30% by weight based on the total weight of the pressure-sensitive adhesive layer in free form. % By weight.
  • the content of bisoprolol is 0.5% by weight or more, a therapeutically effective drug release can be expected.
  • the content of bisoprolol is 40% by weight or less, a sufficient therapeutic effect is obtained and economically advantageous, and when it is 30% by weight or less, it is more advantageous in terms of economics. .
  • the pressure-sensitive adhesive forming the pressure-sensitive adhesive layer is preferably a hydrophobic pressure-sensitive adhesive in order to control the moisture content of the pressure-sensitive adhesive layer and from the viewpoint of skin adhesiveness. It is preferable to form a layer.
  • the acrylic pressure-sensitive adhesive is preferable from the viewpoint of moisture permeability and drug solubility.
  • the acrylic pressure-sensitive adhesive is preferably 30% by weight to 75% by weight, more preferably 35% by weight to 70% by weight with respect to the total weight of the pressure-sensitive adhesive layer in order to give sufficient adhesiveness to the pressure-sensitive adhesive layer.
  • acrylic pressure-sensitive adhesive examples include acrylic acid-based pressure-sensitive adhesives mainly composed of a polymer containing (meth) acrylic acid alkyl ester having 2 to 18 carbon atoms in the alkyl group as a first monomer.
  • acrylic polymer examples include homopolymers of (meth) acrylic acid alkyl esters or copolymers thereof.
  • the alkyl having 2 to 18 carbon atoms in the (meth) acrylic acid alkyl ester is preferably a linear or branched alkyl having 4 to 12 carbon atoms.
  • the (meth) acrylic acid alkyl ester examples include (meth) acrylic acid butyl ester, (meth) acrylic acid t-butyl ester, (meth) acrylic acid pentyl ester, (meth) acrylic acid hexyl ester, (Meth) acrylic acid heptyl ester, (meth) acrylic acid octyl ester, (meth) acrylic acid isooctyl ester, (meth) acrylic acid nonyl ester, (meth) acrylic acid isononyl ester, (meth) acrylic acid decyl ester, Examples include (meth) acrylic acid undecyl ester, (meth) acrylic acid dodecyl ester, (meth) acrylic acid 2-ethylhexyl ester, and the like.
  • the (meth) acrylic acid alkyl ester is contained in the monomer component to be polymerized in a proportion of preferably 50% by weight or more, more preferably 60% by weight or more.
  • the acrylic polymer may be a copolymer polymerized by containing a second monomer copolymerizable with the (meth) acrylic acid alkyl ester, and the second monomer.
  • Examples of the body include monomers having a functional group that can serve as a crosslinking point when a crosslinking agent is used.
  • monomers having neither a carboxyl group nor a sulfonyl group such as hydroxyethyl (meth) acrylate (for example, 2-hydroxyethyl (meth) acrylate), hydroxypropyl (meth) acrylate, glycidyl (meth) acrylate Ethylene glycol diacrylate, hydroxyethyl (meth) acrylamide and the like; monomers having a carboxyl group, such as (meth) acrylic acid, itaconic acid, maleic acid, mesaconic acid, citraconic acid, glutaconic acid and the like. These 2nd monomers can be used 1 type or in combination of 2 or more types.
  • a polymer obtained by containing a third monomer in addition to the second monomer may be used.
  • These third monomers can be used for adjusting the cohesive force of the pressure-sensitive adhesive layer and adjusting the solubility and release of bisoprolol.
  • the third monomer include vinyl esters such as vinyl acetate and vinyl propionate; vinyl ethers such as methyl vinyl ether and ethyl vinyl ether; vinyl amides such as N-vinyl-2-pyrrolidone and N-vinyl caprolactam.
  • These third monomers can be used alone or in combination of two or more.
  • a first monomer particularly 2-ethylhexyl acrylate
  • a second monomer particularly acrylic acid
  • a copolymer obtained by blending a third monomer particularly N-vinyl-2-pyrrolidone in a weight ratio of about 40 to 99.9: 0.1 to 10: 0 to 30 is preferable.
  • the acrylic pressure-sensitive adhesive may be subjected to physical crosslinking by radiation irradiation such as ultraviolet irradiation or electron beam irradiation, isocyanate compound such as trifunctional isocyanate, organic peroxide, organic metal salt, metal alcoholate, metal You may perform the chemical crosslinking process using various crosslinking agents, such as a chelate compound and a polyfunctional compound (Polyfunctional external crosslinking agent, multifunctional internal crosslinking monomers, such as diacrylate and dimethacrylate, etc.).
  • radiation irradiation such as ultraviolet irradiation or electron beam irradiation
  • isocyanate compound such as trifunctional isocyanate
  • organic peroxide organic metal salt
  • metal alcoholate metal You may perform the chemical crosslinking process using various crosslinking agents, such as a chelate compound and a polyfunctional compound (Polyfunctional external crosslinking agent, multifunctional internal crosslinking monomers, such as diacrylate and dimethacrylate, etc.).
  • the rubber-based pressure-sensitive adhesive has particularly high drug release properties from the pressure-sensitive adhesive layer containing the pressure-sensitive adhesive, and it is easy to control the drug release, and there is no possibility that a reactive functional group remains. This is advantageous because of its high stability.
  • the content of the rubber-based pressure-sensitive adhesive is preferably 15% by weight to 60% by weight and more preferably 15% by weight to 55% by weight with respect to the total weight of the pressure-sensitive adhesive layer.
  • the rubber-based pressure-sensitive adhesive is not particularly limited, and examples thereof include a rubber-based pressure-sensitive adhesive mainly composed of at least one selected from polyisobutylene, polyisoprene, butyl rubber, and styrene-diene-styrene copolymer.
  • polyisobutylene is preferably used from the viewpoint of high drug stability and achieving both necessary adhesive strength and cohesive strength.
  • polyisobutylene may be used alone or with a molecular weight of Two or more different polyisobutylenes may be used.
  • the content of polyisobutylene is preferably 15% by weight to 60% by weight, more preferably 15% by weight to 55% by weight based on the total weight of the pressure-sensitive adhesive layer. % By weight. If the content of polyisobutylene relative to the total weight of the pressure-sensitive adhesive layer is less than 15% by weight, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer, while if it exceeds 60% by weight, the pressure-sensitive adhesive There is a risk that the skin adhesion and tack of the layer may be reduced.
  • the molecular weight of polyisobutylene is not particularly limited, but the viscosity average molecular weight is preferably 40,000 to 5,500,000, and 45,000 to More preferably, it is 5,000,000. If the viscosity average molecular weight is less than 40,000, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer. On the other hand, if it exceeds 5,500,000, the adhesiveness and tackiness of the pressure-sensitive adhesive layer may be reduced. May decrease.
  • polyisobutylene having different molecular weights it is preferable to contain two or more types of polyisobutylene having different molecular weights in order to easily achieve appropriate cohesion, moderate flexibility and skin adhesiveness.
  • two or more polyisobutylenes having different molecular weights refers to polyisobutylene having molecular weight distribution peaks measured by gel permeation chromatography (GPC) in two or more independent regions. Each polyisobutylene generally has one molecular weight distribution peak. Therefore, “two or more polyisobutylenes having different molecular weights” contain, for example, two or more polyisobutylenes having different viscosity average molecular weights.
  • the polyisobutylene is preferably composed of, for example, a first polyisobutylene and a second polyisobutylene having a molecular weight relatively lower than that of the first polyisobutylene.
  • the first polyisobutylene can impart an appropriate cohesive force to the pressure-sensitive adhesive layer, and the second polyisobutylene can provide an appropriate flexibility and skin adhesiveness to the pressure-sensitive adhesive layer.
  • the molecular weights of the first polyisobutylene and the second polyisobutylene are not particularly limited, but in order to obtain good skin adhesion and sufficient release of bisoprolol,
  • the viscosity average molecular weight is preferably 1,800,000 to 5,500,000, more preferably 2,000,000 to 5,000,000, and the viscosity average molecular weight of the second polyisobutylene is preferably 40,000 000 to 85,000, more preferably 45,000 to 65,000.
  • the viscosity average molecular weight of the first polyisobutylene is less than 1,800,000, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer, and if it exceeds 5,500,000, There is a possibility that the adhesiveness and tackiness of the agent layer may be lowered. Further, if the viscosity average molecular weight of the second polyisobutylene is less than 40,000, the pressure-sensitive adhesive layer may feel sticky or may contaminate the skin surface, while if it exceeds 85,000, the pressure-sensitive adhesive. There is a risk that the skin adhesion and tack of the layer may be reduced.
  • the 1st and 2nd polyisobutylene can be used in combination of 2 or more type within the range of each molecular weight distribution.
  • the viscosity average molecular weight is a Staudinger index (J 0 ) calculated from the flow time at 20 ° C. of the capillary of the Ubbelohde viscometer by the Schulz-Blaschke equation (the following equation (1)), It refers to a value determined by the following equation (2) using the J 0 value.
  • the total content of polyisobutylene is preferably 15% by weight to 60% by weight, more preferably 15% by weight with respect to the total weight of the pressure-sensitive adhesive layer. % By weight to 55% by weight. If the total content of polyisobutylene is less than 15% by weight, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer. On the other hand, if the total content exceeds 60% by weight, Tack may be reduced.
  • the blending weight ratio (a: b) of the first polyisobutylene (a) and the second polyisobutylene (b) is preferably The ratio is 1: 0.1 to 1: 3, more preferably 1: 0.1 to 1: 2.5, and still more preferably 1: 0.3 to 1: 2.
  • the blending weight ratio (b / a) of the second polyisobutylene (b) to the first polyisobutylene (a) exceeds 3
  • the internal cohesive force of the pressure-sensitive adhesive layer decreases.
  • it is less than 0.1 the skin adhesive force of the pressure-sensitive adhesive layer may be greatly reduced.
  • a tackifier known in the field of patch preparations.
  • tackifiers include petroleum resins (for example, aromatic petroleum resins and aliphatic petroleum resins), terpene resins, rosin resins, coumarone indene resins, styrene resins (for example, styrene resins, ⁇ -Methylstyrene resin), hydrogenated petroleum resin (for example, alicyclic saturated hydrocarbon resin) and the like.
  • alicyclic saturated hydrocarbon resins are preferable because the storage stability of bisoprolol is improved.
  • the tackifier can be used singly or in combination of two or more. When two or more types are used in combination, for example, resins having different types and softening points may be combined.
  • the content of the tackifier is preferably 10% to 55% by weight, more preferably 10% to 50% by weight, particularly preferably 10% to 45% by weight, based on the total weight of the pressure-sensitive adhesive layer. . If the content of the tackifier is less than 10% by weight, tack and cohesive force may be poor. On the other hand, if the content exceeds 55% by weight, the pressure-sensitive adhesive layer becomes hard and the skin adhesiveness tends to be lowered.
  • the softening point of the tackifier is preferably 90 ° C to 150 ° C, more preferably 95 ° C to 145 ° C.
  • the softening point in the present invention is a value measured by the ring and ball method.
  • the pressure-sensitive adhesive layer may contain an organic liquid component having fluidity at room temperature (25 ° C.).
  • the organic liquid component is a liquid organic component that is added in addition to the drug bisoprolol and is particularly compatible with other components of the pressure-sensitive adhesive layer (for example, pressure-sensitive adhesive, tackifier). It is not limited.
  • As the organic liquid component fatty acid alkyl esters and long-chain alcohols are preferably used because they greatly contribute to promoting absorption of bisoprolol and improving the solubility of bisoprolol in the pressure-sensitive adhesive layer. You may use an organic liquid component individually by 1 type or in combination of 2 or more types.
  • fatty acid alkyl ester examples include fatty acid alkyl esters formed from higher fatty acids having 12 to 16 carbon atoms, preferably 12 to 14 carbon atoms, and lower monohydric alcohols having 1 to 4 carbon atoms.
  • Preferred higher fatty acids include lauric acid (carbon number 12), myristic acid (carbon number 14), and palmitic acid (carbon number 16), and myristic acid is more preferable.
  • the monohydric alcohol include methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, and the like, preferably isopropyl alcohol. Therefore, isopropyl myristate is most preferable as the fatty acid alkyl ester, and by using this compound, absorption enhancement of bisoprolol, improvement in solubility, and drug utilization can be achieved at a high level.
  • Examples of the long-chain alcohol include saturated or unsaturated long-chain alcohols having 12 to 28 carbon atoms, preferably 12 to 24 carbon atoms, and saturated long-chain alcohols are preferable from the viewpoint of storage stability. used. Moreover, as said long chain alcohol, a linear or branched long chain alcohol is mentioned, These can be mixed and used. Examples of such linear alcohols include 1-dodecanol, 1-tetradecanol, 1-hexadecanol, stearyl alcohol, etc. Among them, 1-dodecanol is excellent in compatibility with polyisobutylene and stability of bisoprolol. Is preferable.
  • a branched long-chain alcohol having 16 to 28 carbon atoms preferably 18 to 24 carbon atoms
  • Specific examples include 2-hexyldecanol, isostearyl alcohol, 2-octyldodecanol, and 2-decyltetradecanol.
  • 2-octyldodecanol is excellent in compatibility with polyisobutylene and dissolves bisoprolol. It is preferable at the point which can improve property.
  • the blending weight ratio (c: d) of the fatty acid alkyl ester (c) and the long-chain alcohol (d) is preferably 1: 0.01 to 1: 0.5, more preferably 1: 0.01 to 1: 0. .4, more preferably 1: 0.05 to 1: 0.4.
  • the organic liquid component often acts effectively as a permeation enhancer, and in that case, the skin permeability of bisoprolol is improved by increasing the content of the organic liquid component. That is, by containing a large amount of an organic liquid component in the pressure-sensitive adhesive layer, the composition has a higher skin permeability and can easily control the skin permeability. Therefore, it can be said to be an ideal pressure-sensitive adhesive composition as a patch preparation. Moreover, moderate softness
  • flexibility and skin adhesiveness can be provided to an adhesive layer by containing an organic liquid component in an adhesive layer.
  • the content of the organic liquid component is preferably 5% by weight to 70% by weight with respect to the total weight of the pressure-sensitive adhesive layer. More preferably, it is 10 wt% to 65 wt%, and further preferably 20 wt% to 50 wt%.
  • the pressure-sensitive adhesive layer comprises a liquid or paste-like organic component other than the above as necessary.
  • a dissolution aid can be blended.
  • Such a solubilizing agent has excellent compatibility with the pressure-sensitive adhesive, sufficiently dissolves bisoprolol, has a low risk of bleeding out of the pressure-sensitive adhesive layer (bleed), and does not adversely affect the adhesive properties and drug release properties. Anything is acceptable.
  • esters of fatty acids such as oleic acid, myristic acid and capric acid, organic acids such as dicarboxylic acids such as adipic acid and sebacic acid, and alcohols such as ethanol and 2-propanol; glycerin and propylene glycol Polyhydric alcohols such as diesters and triesters thereof; Esters of polyhydric alcohols and organic acids such as triacetin; Polyethers such as polyethylene glycol, polypropylene glycol, polyoxyethylene hydrogenated castor oil; Other crotamitons, etc. Is mentioned.
  • an appropriate filler can be contained in the pressure-sensitive adhesive layer as desired.
  • Such fillers are not particularly limited, but include silica, titanium oxide, zinc oxide, magnesium oxide, iron oxide, aluminum hydroxide, talc, kaolin, bentonite, barium sulfate, calcium carbonate and other inorganic fine particles, lactose, carbon black And organic fine particles such as polyvinylpyrrolidone, polyester, polyolefin, polyurethane, polyamide, cellulose, and acrylic resin, and fibers such as polyester, polyolefin, polyurethane, polyamide, cellulose, acrylic resin, and glass.
  • an appropriate softening agent or tack can be imparted to the pressure-sensitive adhesive layer by adding an appropriate softening agent to the pressure-sensitive adhesive layer.
  • the softening agent is not particularly limited, and examples thereof include liquid rubbers such as liquid polybutene and liquid polyisoprene, and liquid hydrocarbons such as liquid paraffin, squalane and squalene among organic liquid components.
  • a cover tape or the like may be applied so as to cover a part or the entire surface of the patch preparation of the present invention to reinforce the skin adhesiveness and supplement the adhesion to the skin.
  • the first polyisobutylene when used as the pressure-sensitive adhesive, it becomes possible to contain a large amount of an organic liquid component. As a result, the effect of promoting the absorption of the drug by the organic liquid component and the effect of improving the solubility are sufficient. Can get to. As a result, it is possible to suppress a reduction in cohesive force and to obtain a patch preparation with no adhesive residue or the like. Further, by using a tackifier that is higher in the temperature range of the softening point described above, not only the cohesive force but also the skin adhesion can be improved at the same time.
  • the thickness of the pressure-sensitive adhesive layer is usually 10 ⁇ m to 300 ⁇ m, preferably 10 ⁇ m to 250 ⁇ m, and more preferably 15 ⁇ m to 250 ⁇ m.
  • the moisture content of the pressure-sensitive adhesive layer is 10,000 ppm or less, preferably 200 ppm to 10,000 ppm.
  • the lower limit value of the preferable range of the moisture content of the pressure-sensitive adhesive layer is, for example, 200 ppm, 300 ppm, 400 ppm, 500 ppm, 600 ppm, 700 ppm, 800 ppm, 900 ppm, 1,000 ppm from the viewpoint of the possibility of moisture control during the manufacture of the patch preparation. 1,500 ppm, 2,000 ppm, 2,500 ppm, 3,000 ppm, 3,500 ppm or 4,000 ppm.
  • the upper limit value of the preferable moisture content of the pressure-sensitive adhesive layer is, for example, 10,000 ppm, 9,500 ppm, 9,000 ppm, 8,500 ppm, 8,000 ppm, 7,500 ppm, 7, 000 ppm, 6,500 ppm, 6,000 ppm, 5,500 ppm or 5,000 ppm.
  • the moisture content of the pressure-sensitive adhesive layer means the ratio of the weight of water contained in the pressure-sensitive adhesive layer (the ratio of the weight of water to the total weight of the pressure-sensitive adhesive layer) measured by the Karl Fischer coulometric titration method. In this specification, it is a value measured under the measurement conditions described in the examples described later.
  • the moisture content of the adhesive layer of the patch preparation varies depending on the relative humidity of the external environment (atmosphere) and converges to the equilibrium moisture content at that temperature and humidity with the passage of time. That is, when the relative humidity in the external environment (atmosphere) is high, the pressure-sensitive adhesive layer absorbs and adsorbs moisture, and the moisture content of the pressure-sensitive adhesive layer increases. Conversely, when the relative humidity of the external environment (atmosphere) is low, the moisture content of the pressure-sensitive adhesive layer decreases due to the suppression of moisture adsorption to the pressure-sensitive adhesive layer and the release of moisture from the pressure-sensitive adhesive layer. .
  • the moisture content of the pressure-sensitive adhesive layer can be controlled by adjusting the temperature and / or relative humidity of the external environment (atmosphere).
  • adjustment of the temperature and relative humidity of the external environment (atmosphere) can be appropriately performed with a known air conditioner.
  • the atmosphere of the punching process and the packaging stage is maintained at a temperature of 20 ⁇ 10 ° C. and a relative humidity of 30 ⁇ 10%.
  • the water content of the pressure-sensitive adhesive layer can be controlled within the above range.
  • a release liner may be laminated on the adhesive surface in order to protect the adhesive surface of the adhesive layer until use.
  • the release liner is not particularly limited.
  • polyester, polyvinyl chloride, which has been subjected to an easy release treatment by applying a silicone resin, a fluorine resin, or the like to the contact surface with the pressure-sensitive adhesive layer A film such as polyvinylidene chloride and polyethylene terephthalate, paper such as high-quality paper and glassine paper, or a laminate film of high-quality paper or glassine paper and polyolefin is used.
  • the thickness of the release liner is preferably 10 ⁇ m to 200 ⁇ m, more preferably 25 ⁇ m to 150 ⁇ m.
  • the release liner is preferably made of a polyester (particularly, polyethylene terephthalate) resin from the viewpoint of barrier properties, cost, and the like. Further, in this case, those having a thickness of about 25 ⁇ m to 100 ⁇ m are preferable from the viewpoint of handleability.
  • the shape of the patch preparation of the present invention is not particularly limited and includes, for example, a tape shape and a sheet shape.
  • the adhesive preparation of the present invention is prepared by, for example, dissolving a pressure-sensitive adhesive composition containing a pressure-sensitive adhesive, bisoprolol, if necessary, a tackifier, an organic liquid component, etc. in an appropriate solvent such as toluene, and applying the obtained solution onto a release liner. It can be produced by drying, forming a pressure-sensitive adhesive layer, and laminating a support on the pressure-sensitive adhesive layer.
  • the pressure-sensitive adhesive solution can be directly applied to a support and dried to form a pressure-sensitive adhesive layer on the support.
  • the patch preparation of the present invention is preferably enclosed in a moisture-permeable bag until use and stored or transported as a package.
  • a method for forming such a package for example, there is a method in which a single patch preparation or a plurality of patch preparations are packaged with a packaging material constituting a moisture-permeable bag body and the periphery is sealed by heat sealing.
  • the packaging material include a sheet-like or film-like material. From the viewpoints of controlling the moisture content of the pressure-sensitive adhesive layer, ease of packaging, and airtightness, the packaging material exhibits moisture impermeability and can be heat-sealed. Is desirable.
  • a plastic sheet having heat sealing properties such as polyethylene, ionomer resin, ethylene-vinyl acetate copolymer, ethylene-vinyl alcohol copolymer, polyacrylonitrile copolymer, polyvinyl alcohol copolymer, It is preferable to use a packaging material in which a gas or moisture impermeable film such as a polyester film or a metal foil is laminated.
  • a gas or moisture impermeable film By using a gas or moisture impermeable film, the moisture content of the pressure-sensitive adhesive layer can be controlled as described above without having to enclose the desiccant in the package or containing the desiccant in the packaging material itself. it can.
  • the packaging material one having a thickness of 10 ⁇ m to 200 ⁇ m is usually used.
  • an acrylonitrile-based resin having a high barrier property is used for the innermost layer (the layer located on the proximal side of the bisoprolol-containing patch preparation when the bisoprolol-containing patch preparation is sealed in a moisture-permeable bag). More preferred.
  • the acrylonitrile-based resin is preferably a copolymer having acrylonitrile as a main structural unit from the viewpoint of uniformity of properties of the acrylonitrile-based resin layer, and the copolymer has at least acrylonitrile, butadiene, etc. as the structural unit.
  • the rubber component and / or a copolymer containing an alkyl (meth) acrylic acid alkyl ester having 1 to 6 carbon atoms is preferable.
  • the content of acrylonitrile is preferably 50% by weight to 90% by weight, and particularly preferable copolymer is 50% by weight to 90% by weight of acrylonitrile, and 2% by weight of a rubber component such as butadiene.
  • It is a copolymer obtained by copolymerizing a monomer component having a composition of ⁇ 12 wt% and (meth) acrylic acid alkyl ester having an alkyl group having 1 to 6 carbon atoms of 8 wt% to 38 wt%.
  • the copolymer may be in random copolymerization, block copolymerization, or graft copolymerization, but is characterized by the characteristics of polyacrylonitrile having excellent non-adsorptivity to physiologically active components and rubber having excellent shock absorption.
  • a graft copolymerization form capable of efficiently having the characteristics of the components is preferable, and random copolymerization or block copolymerization may be appropriately added as long as the characteristics are not inhibited.
  • composition analysis of the acrylonitrile-type resin in this invention is based on the following method. That is, the CHN elemental analysis is performed on the sample obtained by scraping the acrylonitrile-based resin layer from the packaging material, and the acrylonitrile content is calculated from the nitrogen content. Further, according to the spectra of 1 H-NMR and 13 C-NMR (in heavy dimethyl sulfoxide (DMSO), 80 ° C.), the rubber component and the molecule of the (meth) acrylic acid alkyl ester component in which the alkyl group has 1 to 6 carbon atoms The structure and weight ratio are determined, and the weight ratio of the three components is determined.
  • DMSO heavy dimethyl sulfoxide
  • the thickness of the acrylonitrile-based resin layer is appropriately set according to the type of the patch preparation, and is not particularly limited. However, the non-permeability and non-adsorption property to the physiologically active ingredient in the patch preparation are satisfactorily exhibited, and moisture From the viewpoint of ensuring appropriate flexibility and rigidity as a packaging material for a patch preparation while having impermeability, it is preferably 5 ⁇ m to 100 ⁇ m, more preferably 5 ⁇ m to 80 ⁇ m, and most preferably 5 ⁇ m to 50 ⁇ m.
  • the adhesive component flows out from the side of the patch preparation, there is a concern that the handling properties such as removal from the package may deteriorate, so embossing may be applied to the packaging material or the aforementioned release liner part may be applied. It is preferable to devise packaging forms such as dry edge processing that is slightly larger than the preparation body, or blister molding that is processed so that the contact area is small.
  • the patch preparation of the present invention can be used by taking out the patch preparation by tearing the above-mentioned package immediately before use, etc., peeling off the release liner and sticking the exposed adhesive surface to the skin surface.
  • the usage of the patch preparation of the present invention varies depending on the age, weight, symptoms, etc. of the patient.
  • the application area of the patch preparation of the present invention can be considered in order to achieve administration of an effective amount of bisoprolol while adopting the maximum value of the permeation rate of bisoprolol described above to human skin.
  • the patch area of the patch preparation is preferably 3 cm 2 to 50 cm 2 , more preferably 3 cm 2 to 48 cm 2 , still more preferably 4 cm 2 to 45 cm 2 . If the application area of the patch preparation is smaller than 3 cm 2 , the application operation may be difficult, and if it is larger than 50 cm 2 , the patient may be stressed at the time of application. When a strong medicinal effect is required, two or more sheets can be attached simultaneously.
  • the maximum value of bisoprolol release rate immediately after skin application until 24 hours is 30 ⁇ g / cm 2 / hour or less, and the bisoprolol release rate after 24 hours after skin application is 10 ⁇ g / cm. 2 / hour or less.
  • part or % means “part by weight” or “% by weight”.
  • alicyclic saturated hydrocarbon resin tackifier
  • the obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 ⁇ m) so that the thickness after drying was 160 ⁇ m, and this was applied at 100 ° C. for 5 minutes in a hot air circulating dryer. It dried and the adhesive layer was formed.
  • the peripheral part of the patch preparation was pressurized (4.9 MPa) to obtain a bisoprolol-containing patch preparation.
  • the moisture content of the layer was adjusted.
  • Example 2 Under an inert gas atmosphere, 70.0 parts of 2-ethylhexyl acrylate, 5.0 parts of hydroxyethylacrylamide, and 25.0 parts of N-vinyl-2-pyrrolidone, and azobisisobutyronitrile as a polymerization initiator An acrylic pressure-sensitive adhesive solution was prepared by solution polymerization of 0.2 parts in ethyl acetate at 60 ° C. 65.0 parts of this acrylic pressure-sensitive adhesive solution, 30.0 parts of isopropyl myristate as an organic liquid component, and 5.0 parts of bisoprolol (free body) are mixed, and a viscous ethyl acetate solution of the pressure-sensitive adhesive composition is mixed. Prepared.
  • the obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 ⁇ m) so that the thickness after drying was 45 ⁇ m, and this was applied in a hot air circulating dryer at 100 ° C. for 5 minutes. It dried and formed the adhesive layer.
  • the moisture content of the layer was adjusted.
  • the peripheral part of the patch preparation was pressurized in the same manner as in Example 1 to obtain a bisoprolol-containing patch preparation.
  • the water content of the patch preparation during punching and packaging was not adjusted.
  • the obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 ⁇ m) so that the thickness after drying was 45 ⁇ m, and this was applied in a hot-air circulating dryer at 100 ° C. for 5 minutes. It dried and the adhesive layer was formed.
  • PET polyethylene terephthalate
  • the peripheral part of the patch preparation was pressurized in the same manner as in Example 1 to obtain a bisoprolol-containing patch preparation.
  • the water content of the patch preparation during punching and packaging was not adjusted.
  • Test Example 1 Moisture content of pressure-sensitive adhesive layer Each bisoprolol taken out of the package of each of the above Examples and Comparative Examples in an environment controlled at a temperature of 23 ⁇ 2 ° C and a relative humidity of 40 ⁇ 5% Each of the contained patch preparations was punched out to 7.5 cm 2 to prepare a test piece. Thereafter, the release liner was removed from the test piece and put into a moisture vaporizer. In addition, said process was completed within 1 minute after opening of a package. The test piece was heated at 140 ° C.
  • Table 1 shows the results of Test Examples 1 and 2.
  • the moisture content of the pressure-sensitive adhesive layer was 395 ppm and 6,740 ppm, respectively, and the content of related substances immediately after sample preparation was 0.5%.
  • the content of related substances was maintained at a low level of 1.0% or less even after storage at 50 ° C. for 1 month.
  • the moisture content in the pressure-sensitive adhesive layer exceeds 10,000 ppm, and after storing at 50 ° C. for 1 month, the content of related substances is 2.0%. This is the result, indicating that the stability of bisoprolol in the patch preparation is poor.
  • the packaging body of the bisoprolol containing medicated patch excellent in usability and portability can be provided.

Abstract

The present invention relates to: a bisoprolol-containing adhesive patch which comprises a supporting body and an adhesive layer that is formed on at least one surface of the supporting body and contains bisoprolol, and wherein the adhesive layer has a moisture content of 10,000 ppm or less; and a package of a bisoprolol-containing adhesive patch, which is obtained by sealing the bisoprolol-containing adhesive patch in a bag that has resistance to water vapor permeation. A bisoprolol-containing adhesive patch according to the present invention achieves excellent long-term stability of bisoprolol that is contained in the adhesive layer. In addition, a package of a bisoprolol-containing adhesive patch according to the present invention has excellent usability and portability.

Description

ビソプロロール含有貼付製剤およびその包装体Patch preparation containing bisoprolol and its package
 本発明はビソプロロール含有貼付製剤およびその包装体に関する。 The present invention relates to a patch preparation containing bisoprolol and a package thereof.
 近年、薬物を生体内へ投与する手段として、薬物が含有された粘着シートを皮膚に貼付する貼付製剤が採用されている。このような貼付製剤では、ポリエステルやポリエチレンなどのプラスチック製の支持体の片面に、経皮吸収性薬物を含有させた粘着剤層が積層され、当該粘着剤層の露出された面が剥離ライナーで被覆されている。通常、このような貼付製剤は、含有される経皮吸収性薬物の揮散や湿度の影響を防止するために、水分に対し不透過性の包装材にて個別に包装されている。 In recent years, as a means for administering a drug into a living body, a patch preparation in which an adhesive sheet containing the drug is applied to the skin has been adopted. In such a patch preparation, an adhesive layer containing a transdermally absorbable drug is laminated on one side of a plastic support such as polyester or polyethylene, and the exposed surface of the adhesive layer is a release liner. It is covered. Usually, such a patch preparation is individually packaged with a packaging material that is impermeable to moisture in order to prevent volatilization of contained transdermal drug and the influence of humidity.
 交感神経のβ1受容体の高選択性拮抗薬(βブロッカー)であるビソプロロールは、本態性高血圧、狭心症、不整脈の改善に使用されており、そのフマル酸塩が錠剤として経口的に投与されている。しかし、経口投与の場合、効果の持続性に欠けることや、投与後一時的に必要以上の血中濃度上昇が認められ、副作用が起こりやすい等の欠点があり、これを改善するためにビソプロロールの貼付製剤が望まれている。 Bisoprolol, a highly selective sympathetic β1 receptor antagonist (β-blocker), is used to improve essential hypertension, angina pectoris, and arrhythmias, and its fumarate is administered orally as a tablet. ing. However, in the case of oral administration, there are drawbacks such as lack of sustainability of the effect, temporary increase in blood concentration temporarily necessary after administration, and side effects are likely to occur, and in order to improve this, bisoprolol A patch preparation is desired.
 上記ビソプロロール含有貼付製剤に関し、特許文献1には、ビソプロロールの加水分解反応を抑制し、その保存安定性を向上させるべく、該貼付製剤が包装袋に収容され、前記包装袋の内部の25℃における相対湿度が25%以下に維持されている貼付製剤入り包装袋が開示されている。しかしながら、前記包装袋は、乾燥剤を必要としており、包装体を形成した際に嵩高く、携帯や使用において不便であった。
 また、特許文献2には、粘着剤層の着色を防止し、ドネペジルの放出性の劣化を抑制する目的で、粘着剤層の含水率を1,000ppm~8,000ppmとした貼付製剤が開示されている。しかしながら、前記特許文献は、貼付製剤に含有されたビソプロロールの経時安定性の向上を示唆するものではなく、また、ビソプロロール含有貼付製剤への適用の可能性についても、何ら示唆していない。
With regard to the above-mentioned bisoprolol-containing patch preparation, Patent Document 1 discloses that the patch preparation is contained in a packaging bag in order to suppress the hydrolysis reaction of bisoprolol and improve its storage stability, and at 25 ° C. inside the packaging bag. A packaging bag containing a patch preparation in which the relative humidity is maintained at 25% or less is disclosed. However, the packaging bag requires a desiccant, is bulky when a package is formed, and is inconvenient to carry and use.
Patent Document 2 discloses a patch preparation in which the moisture content of the pressure-sensitive adhesive layer is 1,000 ppm to 8,000 ppm for the purpose of preventing the pressure-sensitive adhesive layer from being colored and suppressing the degradation of donepezil release. ing. However, the above-mentioned patent document does not suggest improvement of the temporal stability of bisoprolol contained in the patch preparation, nor does it suggest any possibility of application to the bisoprolol-containing patch preparation.
国際公開第2005/072716号International Publication No. 2005/072716 国際公開第2009/145177号International Publication No. 2009/145177
 本発明は、粘着剤層に含有されるビソプロロールの経時安定性に優れるビソプロロール含有貼付製剤を提供すること、および、使用性および携帯性に優れるビソプロロール含有貼付製剤の包装体を提供することを目的とする。 It is an object of the present invention to provide a bisoprolol-containing patch preparation excellent in stability over time of bisoprolol contained in an adhesive layer, and to provide a package of a bisoprolol-containing patch preparation excellent in usability and portability. To do.
 本発明者らは、ビソプロロール含有貼付製剤の粘着剤層中におけるビソプロロールの経時安定性の向上を図るべく鋭意検討した結果、ビソプロロールの経時的な安定性が含水率と有意な相関関係にあることを見出し、粘着剤層の含水率を適度にコントロールすることにより、ビソプロロール含有貼付製剤の包装に際し、乾燥剤を使用しなくてもビソプロロールの経時的な加水分解反応を抑制できることを見出し、本発明を完成するに至った。 As a result of intensive investigations aimed at improving the stability of bisoprolol over time in the adhesive layer of the bisoprolol-containing patch preparation, the inventors have found that the stability of bisoprolol over time has a significant correlation with the moisture content. The present inventors have found that by controlling the water content of the pressure-sensitive adhesive layer appropriately, the hydrolysis reaction over time of bisoprolol can be suppressed without using a desiccant when packaging a bisoprolol-containing patch preparation. It came to do.
 すなわち、本発明は以下の通りである。
(1)支持体と、その少なくとも片面に形成された、ビソプロロールを含有する粘着剤層とを有し、該粘着剤層の含水率が10,000ppm以下である、ビソプロロール含有貼付製剤。
(2)前記粘着剤層の含水率が200ppm~10,000ppmである、(1)に記載のビソプロロール含有貼付製剤。
(3)前記粘着剤層が、アクリル系粘着剤およびゴム系粘着剤からなる群より選択される1種または2種以上の粘着剤を含有する、(1)または(2)に記載のビソプロロール含有貼付製剤。
(4)さらに、前記粘着剤層の粘着面に仮着された剥離ライナーを備える、(1)~(3)のいずれか1つに記載のビソプロロール含有貼付製剤。
(5)(1)~(4)のいずれか1つに記載のビソプロロール含有貼付製剤が、耐透湿性袋体中に封入されている、ビソプロロール含有貼付製剤の包装体。
(6)前記耐透湿性袋体が、アクリロニトリル系樹脂層と、水分不透過性層とが積層されてなる包装材を、該アクリロニトリル系樹脂層が、前記ビソプロロール含有貼付製剤の近位側に位置するように密封したものである、(5)に記載の包装体。
(7)前記耐透湿性袋体内に乾燥剤が封入されていない、(5)または(6)に記載の包装体。
(8)前記耐透湿性袋体が、乾燥剤を含有しない包装材により形成されている、(5)~(7)のいずれか1つに記載の包装体。
That is, the present invention is as follows.
(1) A bisoprolol-containing patch preparation comprising a support and a pressure-sensitive adhesive layer containing bisoprolol formed on at least one surface thereof, wherein the water content of the pressure-sensitive adhesive layer is 10,000 ppm or less.
(2) The bisoprolol-containing patch preparation according to (1), wherein the pressure-sensitive adhesive layer has a water content of 200 ppm to 10,000 ppm.
(3) Bisoprolol containing according to (1) or (2), wherein the pressure-sensitive adhesive layer contains one or more pressure-sensitive adhesives selected from the group consisting of acrylic pressure-sensitive adhesives and rubber-based pressure-sensitive adhesives Patch preparation.
(4) The bisoprolol-containing patch preparation according to any one of (1) to (3), further comprising a release liner temporarily attached to the adhesive surface of the adhesive layer.
(5) A package of a bisoprolol-containing patch preparation in which the bisoprolol-containing patch preparation according to any one of (1) to (4) is enclosed in a moisture-permeable bag.
(6) The moisture-permeable bag is a packaging material in which an acrylonitrile-based resin layer and a moisture-impermeable layer are laminated, and the acrylonitrile-based resin layer is positioned on the proximal side of the bisoprolol-containing patch preparation. The package according to (5), which is hermetically sealed.
(7) The package according to (5) or (6), wherein a desiccant is not enclosed in the moisture-permeable bag.
(8) The packaging body according to any one of (5) to (7), wherein the moisture-permeable bag body is formed of a packaging material containing no desiccant.
 本発明によれば、ビソプロロール含有貼付製剤の包装に際して乾燥剤を用いることなく、粘着剤層中のビソプロロールの経時的な加水分解を抑制することができるので、経時安定性および信頼性が高められたビソプロロール含有貼付製剤を実現することができ、また、使用性および携帯性に優れるビソプロロール含有貼付製剤の包装体を提供することができる。これにより、患者のQOL(クオリティー オブ ライフ)および経済性が高められる。 According to the present invention, the time-dependent hydrolysis of bisoprolol in the pressure-sensitive adhesive layer can be suppressed without using a desiccant when packaging a bisoprolol-containing patch preparation, so that the stability and reliability with time are improved. A bisoprolol-containing patch preparation can be realized, and a package of a bisoprolol-containing patch preparation excellent in usability and portability can be provided. This increases the patient's quality of life (QOL) and economics.
 本発明のビソプロロール含有貼付製剤は、支持体と、支持体の少なくとも片面に形成された、ビソプロロールを含有する粘着剤層とを有する。なお、以下において、本発明のビソプロロール含有貼付製剤を、「本発明の貼付製剤」、あるいは単に「貼付製剤」ということがある。 The bisoprolol-containing patch preparation of the present invention has a support and a pressure-sensitive adhesive layer containing bisoprolol formed on at least one side of the support. In the following, the bisoprolol-containing patch preparation of the present invention may be referred to as “the patch preparation of the present invention” or simply “the patch preparation”.
 本発明において用い得る支持体としては特に限定されないが、実質的に薬物等に対して不透過性を有するもの、すなわち、活性成分であるビソプロロールや添加剤等の粘着剤層に含有される成分が、支持体中を通って背面から失われて含有量の低下を引き起こさないものが好ましい。具体的には、例えば、ポリエステル、ポリアミド、ポリ塩化ビニリデン、ポリエチレン、ポリプロピレン、ポリ塩化ビニル、エチレン-アクリル酸エチル共重合体、ポリテトラフルオロエチレン、アイオノマー樹脂、金属箔等の単独フィルムまたはこれらの積層フィルム等を用いることができる。支持体の厚みは、通常5μm~500μm、好ましくは10μm~200μmである。
 これらのうち、支持体と粘着剤層との接着性(投錨性)を良好にするため、支持体を上記材質からなる無孔のプラスチックフィルムと、多孔質フィルムとの積層フィルムとすることが好ましい。この場合、粘着剤層は多孔質フィルム側に形成することが望ましい。
The support that can be used in the present invention is not particularly limited, but a material that is substantially impermeable to drugs or the like, that is, a component contained in an adhesive layer such as an active ingredient bisoprolol or an additive. Those that pass through the support and are lost from the back are not preferred. Specifically, for example, polyester, polyamide, polyvinylidene chloride, polyethylene, polypropylene, polyvinyl chloride, ethylene-ethyl acrylate copolymer, polytetrafluoroethylene, ionomer resin, a single film such as a metal foil, or a laminate thereof A film or the like can be used. The thickness of the support is usually 5 μm to 500 μm, preferably 10 μm to 200 μm.
Among these, in order to improve the adhesion (throwing property) between the support and the pressure-sensitive adhesive layer, the support is preferably a laminated film of a nonporous plastic film made of the above material and a porous film. . In this case, it is desirable to form the pressure-sensitive adhesive layer on the porous film side.
 上記多孔質フィルムとしては、粘着剤層との投錨性を向上させるものが採用されるが、具体的には紙、織布、不織布、編布、機械的に穿孔処理を施したシート等が挙げられる。
 これらのうち、取り扱い性等の観点から、特に紙、織布、不織布が好ましい。多孔質フィルムは、投錨性向上、貼付製剤全体の柔軟性および貼付操作性等の点から、好ましくは10μm~200μmの範囲の厚みを有するものが採用される。プラスタータイプや粘着テープタイプのような薄手の貼付製剤の場合、好ましくは10μm~100μmの範囲の厚みを有するものが採用される。
As the porous film, one that improves anchoring property with the pressure-sensitive adhesive layer is adopted, and specifically, paper, woven fabric, non-woven fabric, knitted fabric, a mechanically perforated sheet, and the like are mentioned. It is done.
Among these, paper, woven fabric, and non-woven fabric are particularly preferable from the viewpoint of handleability and the like. A porous film having a thickness in the range of 10 μm to 200 μm is preferably used from the viewpoints of improvement of anchoring property, flexibility of the whole patch preparation, sticking operability, and the like. In the case of a thin patch preparation such as a plaster type or an adhesive tape type, one having a thickness in the range of 10 μm to 100 μm is preferably employed.
 また、多孔質フィルムとして織布や不織布を用いる場合、それらの目付量は、好ましくは5g/m~30g/mであり、より好ましくは6g/m~15g/mである。最も好適な支持体としては、厚さ1.5μm~6μmのポリエステルフィルム(好ましくは、ポリエチレンテレフタレートフィルム)と、目付量6g/m~15g/mのポリエステル(好ましくは、ポリエチレンテレフタレート)製不織布との積層フィルムが挙げられる。 When a woven fabric or a non-woven fabric is used as the porous film, the basis weight thereof is preferably 5 g / m 2 to 30 g / m 2 , more preferably 6 g / m 2 to 15 g / m 2 . The most preferable support is a non-woven fabric made of a polyester film (preferably polyethylene terephthalate film) having a thickness of 1.5 μm to 6 μm and a polyester (preferably polyethylene terephthalate) having a basis weight of 6 g / m 2 to 15 g / m 2. And a laminated film.
 本発明の貼付製剤において、粘着剤層はビソプロロールを含有する。ビソプロロールはすでに経口剤として市販されており、錠剤の場合、フマル酸ビソプロロールといった塩の形態で含有されている。本発明の貼付製剤において、ビソプロロールは、フリー体(遊離塩基)のみでなく、薬学的に許容される塩の形態でも粘着剤層に含有させることができるが、塩の形態のビソプロロールはフリー体よりも皮膚透過性が低いため、皮膚透過性の観点からは、ビソプロロールは、フリー体で粘着剤層に含有させることが望ましい。
 本発明の貼付製剤におけるビソプロロールの含有量は、フリー体換算で、粘着剤層の全重量に対し、好ましくは0.5重量%~40重量%であり、より好ましくは0.5重量%~30重量%である。
 ビソプロロールの含有量が0.5重量%以上の場合には、治療に有効な量の薬物放出が期待できる。一方、ビソプロロールの含有量が40重量%以下である場合には、十分な治療効果が得られると共に経済的に有利であり、30重量%以下である場合には、経済的側面においてより有利である。
In the patch preparation of the present invention, the pressure-sensitive adhesive layer contains bisoprolol. Bisoprolol is already marketed as an oral preparation, and in the case of a tablet, it is contained in the form of a salt such as bisoprolol fumarate. In the patch preparation of the present invention, bisoprolol can be contained in the adhesive layer not only in the free form (free base) but also in the form of a pharmaceutically acceptable salt. From the viewpoint of skin permeability, it is desirable that bisoprolol is contained in the pressure-sensitive adhesive layer as a free body.
The content of bisoprolol in the patch preparation of the present invention is preferably 0.5% to 40% by weight and more preferably 0.5% to 30% by weight based on the total weight of the pressure-sensitive adhesive layer in free form. % By weight.
When the content of bisoprolol is 0.5% by weight or more, a therapeutically effective drug release can be expected. On the other hand, when the content of bisoprolol is 40% by weight or less, a sufficient therapeutic effect is obtained and economically advantageous, and when it is 30% by weight or less, it is more advantageous in terms of economics. .
 本発明の貼付製剤において、粘着剤層を形成する粘着剤としては、粘着剤層の含水率をコントロールするため、および皮膚接着性の観点から、疎水性粘着剤が好ましく、非含水系の粘着剤層を形成することが好ましい。かかる疎水性の非含水系粘着剤としては、例えば、アクリル系重合体からなるアクリル系粘着剤;スチレン-ジエン-スチレンブロック共重合体(例えばスチレン-イソプレン-スチレンブロック共重合体、スチレン-ブタジエン-スチレンブロック共重合体など)、ポリイソプレン、ポリイソブチレン、ブチルゴム、ポリブタジエン等のゴム系粘着剤;シリコーンゴム、ジメチルシロキサンベース、ジフェニルシロキサンベース等のシリコーン系粘着剤;ポリビニルメチルエーテル、ポリビニルエチルエーテル、ポリビニルイソブチルエーテル等のビニルエーテル系粘着剤;酢酸ビニル-エチレン共重合体等のビニルエステル系粘着剤;ジメチルテレフタレート、ジメチルイソフタレート、ジメチルフタレート等のカルボン酸成分と、エチレングリコール等の多価アルコール成分とからなるポリエステル系粘着剤等が挙げられ、アクリル系粘着剤およびゴム系粘着剤がより好ましく用いられる。本発明の貼付製剤においては、アクリル系粘着剤およびゴム系粘着剤からなる群より、1種または2種以上を選択して用いることが好ましい。 In the patch preparation of the present invention, the pressure-sensitive adhesive forming the pressure-sensitive adhesive layer is preferably a hydrophobic pressure-sensitive adhesive in order to control the moisture content of the pressure-sensitive adhesive layer and from the viewpoint of skin adhesiveness. It is preferable to form a layer. Examples of such hydrophobic non-water-containing pressure-sensitive adhesives include acrylic pressure-sensitive adhesives composed of acrylic polymers; styrene-diene-styrene block copolymers (for example, styrene-isoprene-styrene block copolymers, styrene-butadiene- Styrene block copolymers, etc.), rubber adhesives such as polyisoprene, polyisobutylene, butyl rubber, polybutadiene; silicone adhesives such as silicone rubber, dimethylsiloxane base, diphenylsiloxane base; polyvinyl methyl ether, polyvinyl ethyl ether, polyvinyl Vinyl ether adhesives such as isobutyl ether; vinyl ester adhesives such as vinyl acetate-ethylene copolymer; carboxylic acid components such as dimethyl terephthalate, dimethyl isophthalate and dimethyl phthalate; Mentioned polyester-based adhesives or the like composed of a polyhydric alcohol component such as glycol are acrylic adhesives and rubber-based adhesives are preferably used. In the patch preparation of the present invention, it is preferable to use one or more selected from the group consisting of an acrylic adhesive and a rubber adhesive.
 アクリル系粘着剤は、透湿性および薬物溶解性の観点からも好ましい。アクリル系粘着剤は、粘着剤層に十分な皮膚接着性を付与するためには、粘着剤層の全重量に対して、好ましくは30重量%~75重量%、より好ましくは35重量%~70重量%、さらに好ましくは40重量%~65重量%含有させる。 An acrylic pressure-sensitive adhesive is preferable from the viewpoint of moisture permeability and drug solubility. The acrylic pressure-sensitive adhesive is preferably 30% by weight to 75% by weight, more preferably 35% by weight to 70% by weight with respect to the total weight of the pressure-sensitive adhesive layer in order to give sufficient adhesiveness to the pressure-sensitive adhesive layer. % By weight, more preferably 40% by weight to 65% by weight.
 アクリル系粘着剤としては、アルキル基の炭素数が2~18の(メタ)アクリル酸アルキルエステルを第1の単量体として含む重合体を主成分とするアクリル酸エステル系粘着剤が挙げられる。当該アクリル系重合体としては、(メタ)アクリル酸アルキルエステルの単独重合体、あるいはこれらの共重合体が挙げられる。ここで、前記(メタ)アクリル酸アルキルエステルにおける炭素数が2~18のアルキルとしては、炭素数が4~12の直鎖または分岐鎖アルキルが好ましい。かかる(メタ)アクリル酸アルキルエステルとしては、具体的には、(メタ)アクリル酸ブチルエステル、(メタ)アクリル酸t-ブチルエステル、(メタ)アクリル酸ペンチルエステル、(メタ)アクリル酸ヘキシルエステル、(メタ)アクリル酸ヘプチルエステル、(メタ)アクリル酸オクチルエステル、(メタ)アクリル酸イソオクチルエステル、(メタ)アクリル酸ノニルエステル、(メタ)アクリル酸イソノニルエステル、(メタ)アクリル酸デシルエステル、(メタ)アクリル酸ウンデシルエステル、(メタ)アクリル酸ドデシルエステル、(メタ)アクリル酸2-エチルヘキシルエステル等が挙げられる。
 上記(メタ)アクリル酸アルキルエステルは、重合される単量体成分中、好ましくは50重量%以上、より好ましくは60重量%以上の割合で含有される。
Examples of the acrylic pressure-sensitive adhesive include acrylic acid-based pressure-sensitive adhesives mainly composed of a polymer containing (meth) acrylic acid alkyl ester having 2 to 18 carbon atoms in the alkyl group as a first monomer. Examples of the acrylic polymer include homopolymers of (meth) acrylic acid alkyl esters or copolymers thereof. Here, the alkyl having 2 to 18 carbon atoms in the (meth) acrylic acid alkyl ester is preferably a linear or branched alkyl having 4 to 12 carbon atoms. Specific examples of the (meth) acrylic acid alkyl ester include (meth) acrylic acid butyl ester, (meth) acrylic acid t-butyl ester, (meth) acrylic acid pentyl ester, (meth) acrylic acid hexyl ester, (Meth) acrylic acid heptyl ester, (meth) acrylic acid octyl ester, (meth) acrylic acid isooctyl ester, (meth) acrylic acid nonyl ester, (meth) acrylic acid isononyl ester, (meth) acrylic acid decyl ester, Examples include (meth) acrylic acid undecyl ester, (meth) acrylic acid dodecyl ester, (meth) acrylic acid 2-ethylhexyl ester, and the like.
The (meth) acrylic acid alkyl ester is contained in the monomer component to be polymerized in a proportion of preferably 50% by weight or more, more preferably 60% by weight or more.
 また、上記アクリル系重合体は、上記(メタ)アクリル酸アルキルエステルと共重合可能な第2の単量体を含有して重合される共重合体であってもよく、かかる第2の単量体としては、架橋剤を用いる際の架橋点となりうる官能基を有する単量体が挙げられる。具体的には、カルボキシル基もスルホニル基も有しない単量体、例えばヒドロキシエチル(メタ)アクリレート(例えば、(メタ)アクリル酸2-ヒドロキシエチル)、ヒドロキシプロピル(メタ)アクリレート、グリシジル(メタ)アクリレート、エチレングリコールジアクリレート、ヒドロキシエチル(メタ)アクリルアミド等;カルボキシル基を有する単量体、例えば(メタ)アクリル酸、イタコン酸、マレイン酸、メサコン酸、シトラコン酸、グルタコン酸等が挙げられる。これらの第2の単量体は1種または2種以上を組み合わせて用いることができる。 The acrylic polymer may be a copolymer polymerized by containing a second monomer copolymerizable with the (meth) acrylic acid alkyl ester, and the second monomer. Examples of the body include monomers having a functional group that can serve as a crosslinking point when a crosslinking agent is used. Specifically, monomers having neither a carboxyl group nor a sulfonyl group, such as hydroxyethyl (meth) acrylate (for example, 2-hydroxyethyl (meth) acrylate), hydroxypropyl (meth) acrylate, glycidyl (meth) acrylate Ethylene glycol diacrylate, hydroxyethyl (meth) acrylamide and the like; monomers having a carboxyl group, such as (meth) acrylic acid, itaconic acid, maleic acid, mesaconic acid, citraconic acid, glutaconic acid and the like. These 2nd monomers can be used 1 type or in combination of 2 or more types.
 さらに、所望により、第2の単量体以外に第3の単量体を含有させて得られる重合体であってもよい。これら第3の単量体は、粘着剤層の凝集力調整や、ビソプロロールの溶解性および放出性の調整のために用いることができる。かかる第3の単量体としては、例えば、酢酸ビニルやプロピオン酸ビニル等のビニルエステル類;メチルビニルエーテル、エチルビニルエーテル等のビニルエーテル類;N-ビニル-2-ピロリドン、N-ビニルカプロラクタム等のビニルアミド類;(メタ)アクリル酸アルキルエステル;(メタ)アクリルアミド、ジメチル(メタ)アクリルアミド等のアミド基含有単量体;(メタ)アクリル酸メトキシエチルエステル(例えば、2-メトキシエチルアクリレート)、(メタ)アクリル酸エトキシエチルエステル等のアルコキシル基含有単量体;スチレン、ビニルピリジン、ビニルイミダゾール、ビニルモルホリン等のビニル系単量体;アクリルアミド類(例えば、N-メチロールアクリルアミド、N,N-ジメチルアミノプロピルアクリルアミド);メトキシノナエチレングリコールアクリレート;アクリロイルモルフォリン;フェノキシポリエチレングリコール(メタ)アクリレートなどが挙げられる。これらの第3の単量体は1種または2種以上を組み合わせて用いることができる。 Further, if desired, a polymer obtained by containing a third monomer in addition to the second monomer may be used. These third monomers can be used for adjusting the cohesive force of the pressure-sensitive adhesive layer and adjusting the solubility and release of bisoprolol. Examples of the third monomer include vinyl esters such as vinyl acetate and vinyl propionate; vinyl ethers such as methyl vinyl ether and ethyl vinyl ether; vinyl amides such as N-vinyl-2-pyrrolidone and N-vinyl caprolactam. ; (Meth) acrylic acid alkyl ester; amide group-containing monomers such as (meth) acrylamide and dimethyl (meth) acrylamide; (meth) acrylic acid methoxyethyl ester (for example, 2-methoxyethyl acrylate), (meth) acrylic Alkoxy group-containing monomers such as acid ethoxyethyl ester; vinyl monomers such as styrene, vinyl pyridine, vinyl imidazole and vinyl morpholine; acrylamides (eg, N-methylol acrylamide, N, N-dimethylaminopropyl acrylate) Amide); methoxynonaethylene glycol acrylate; acryloyl morpholine; and phenoxy polyethylene glycol (meth) acrylate. These third monomers can be used alone or in combination of two or more.
 上記したアクリル系重合体のうち、容易に皮膚接着力を調整できる観点から、例えば、第1の単量体(とりわけアクリル酸2-エチルヘキシル)と、第2の単量体(とりわけアクリル酸)と、第3の単量体(とりわけN-ビニル-2-ピロリドン)とを、40~99.9:0.1~10:0~30程度の重量比で配合して共重合したものが好ましい。 Among the acrylic polymers described above, from the viewpoint of easily adjusting the skin adhesive force, for example, a first monomer (particularly 2-ethylhexyl acrylate), a second monomer (particularly acrylic acid), A copolymer obtained by blending a third monomer (particularly N-vinyl-2-pyrrolidone) in a weight ratio of about 40 to 99.9: 0.1 to 10: 0 to 30 is preferable.
 また、所望により、上記アクリル系粘着剤に、紫外線照射や電子線照射などの放射線照射による物理的架橋、三官能性イソシアネートなどのイソシアネート系化合物や有機過酸化物、有機金属塩、金属アルコラート、金属キレート化合物、多官能性化合物(多官能性外部架橋剤、ジアクリレート、ジメタクリレート等の多官能性内部架橋用モノマー等)などの各種架橋剤を用いた化学的架橋処理を施してもよい。 In addition, if desired, the acrylic pressure-sensitive adhesive may be subjected to physical crosslinking by radiation irradiation such as ultraviolet irradiation or electron beam irradiation, isocyanate compound such as trifunctional isocyanate, organic peroxide, organic metal salt, metal alcoholate, metal You may perform the chemical crosslinking process using various crosslinking agents, such as a chelate compound and a polyfunctional compound (Polyfunctional external crosslinking agent, multifunctional internal crosslinking monomers, such as diacrylate and dimethacrylate, etc.).
 一方、ゴム系粘着剤は、該粘着剤を含む粘着剤層からの薬物放出性が特に高く、薬物放出の制御が容易である点、また、反応性官能基が残存する可能性がなく、薬物の安定性が高い点で有利である。ゴム系粘着剤の含有量は、粘着剤層の全重量に対して、好ましくは15重量%~60重量%、より好ましくは15重量%~55重量%である。 On the other hand, the rubber-based pressure-sensitive adhesive has particularly high drug release properties from the pressure-sensitive adhesive layer containing the pressure-sensitive adhesive, and it is easy to control the drug release, and there is no possibility that a reactive functional group remains. This is advantageous because of its high stability. The content of the rubber-based pressure-sensitive adhesive is preferably 15% by weight to 60% by weight and more preferably 15% by weight to 55% by weight with respect to the total weight of the pressure-sensitive adhesive layer.
 ゴム系粘着剤としては特に限定されないが、例えば、ポリイソブチレン、ポリイソプレン、ブチルゴム、およびスチレン-ジエン-スチレン共重合体から選ばれる少なくとも1種を主成分とするゴム系粘着剤が挙げられる。中でも、薬物安定性が高く、必要な接着力および凝集力を両立できる観点から、ポリイソブチレンが好適に使用されるが、その場合、ポリイソブチレンは1種を単独で用いてもよく、また分子量の異なる2種以上のポリイソブチレンを用いてもよい。 The rubber-based pressure-sensitive adhesive is not particularly limited, and examples thereof include a rubber-based pressure-sensitive adhesive mainly composed of at least one selected from polyisobutylene, polyisoprene, butyl rubber, and styrene-diene-styrene copolymer. Among them, polyisobutylene is preferably used from the viewpoint of high drug stability and achieving both necessary adhesive strength and cohesive strength. In that case, polyisobutylene may be used alone or with a molecular weight of Two or more different polyisobutylenes may be used.
 粘着剤層にポリイソブチレンを1種単独で含有させる場合、ポリイソブチレンの含有量は、粘着剤層の全重量に対して、好ましくは15重量%~60重量%、より好ましくは15重量%~55重量%である。粘着剤層の全重量に対するポリイソブチレンの含有量が15重量%未満であると、粘着剤層に必要な内部凝集力を付与し難くなるおそれがあり、他方、60重量%を超えると、粘着剤層の皮膚接着性やタックが低下するおそれがある。
 また、粘着剤層にポリイソブチレンを1種単独で含有させる場合、ポリイソブチレンの分子量は特に限定されないが、粘度平均分子量が40,000~5,500,000であることが好ましく、45,000~5,000,000であることがより好ましい。粘度平均分子量が40,000未満であると、粘着剤層に必要な内部凝集力を付与し難くなるおそれがあり、他方、5,500,000を超えると、粘着剤層の皮膚接着性やタックが低下するおそれがある。
When polyisobutylene is contained alone in the pressure-sensitive adhesive layer, the content of polyisobutylene is preferably 15% by weight to 60% by weight, more preferably 15% by weight to 55% by weight based on the total weight of the pressure-sensitive adhesive layer. % By weight. If the content of polyisobutylene relative to the total weight of the pressure-sensitive adhesive layer is less than 15% by weight, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer, while if it exceeds 60% by weight, the pressure-sensitive adhesive There is a risk that the skin adhesion and tack of the layer may be reduced.
When the pressure-sensitive adhesive layer contains polyisobutylene alone, the molecular weight of polyisobutylene is not particularly limited, but the viscosity average molecular weight is preferably 40,000 to 5,500,000, and 45,000 to More preferably, it is 5,000,000. If the viscosity average molecular weight is less than 40,000, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer. On the other hand, if it exceeds 5,500,000, the adhesiveness and tackiness of the pressure-sensitive adhesive layer may be reduced. May decrease.
 粘着剤層において、適度な凝集力と、適度な柔軟性および皮膚接着性とを容易に両立させるためには、分子量の異なる2種以上のポリイソブチレンを含有させることが好ましい。本明細書において「分子量の異なる2種以上のポリイソブチレン」とは、ゲルパーミエーションクロマトグラフィー(GPC)により測定される分子量分布のピークを、2つ以上の独立した領域に有するポリイソブチレンをいう。なお、各ポリイソブチレンの分子量分布のピークは概して1つである。よって、「分子量が異なる2種以上のポリイソブチレン」には、例えば、粘度平均分子量が異なる2種以上のポリイソブチレンが含有されている。ポリイソブチレンは、例えば、第1のポリイソブチレンと、第1のポリイソブチレンよりも相対的に分子量の低い第2のポリイソブチレンとから構成されることが好ましい。前記第1のポリイソブチレンは粘着剤層に適度な凝集力を付与し、また第2のポリイソブチレンは粘着剤層に適度な柔軟性および皮膚接着性を付与することができる。 In the pressure-sensitive adhesive layer, it is preferable to contain two or more types of polyisobutylene having different molecular weights in order to easily achieve appropriate cohesion, moderate flexibility and skin adhesiveness. As used herein, “two or more polyisobutylenes having different molecular weights” refers to polyisobutylene having molecular weight distribution peaks measured by gel permeation chromatography (GPC) in two or more independent regions. Each polyisobutylene generally has one molecular weight distribution peak. Therefore, “two or more polyisobutylenes having different molecular weights” contain, for example, two or more polyisobutylenes having different viscosity average molecular weights. The polyisobutylene is preferably composed of, for example, a first polyisobutylene and a second polyisobutylene having a molecular weight relatively lower than that of the first polyisobutylene. The first polyisobutylene can impart an appropriate cohesive force to the pressure-sensitive adhesive layer, and the second polyisobutylene can provide an appropriate flexibility and skin adhesiveness to the pressure-sensitive adhesive layer.
 上記の第1のポリイソブチレンと第2のポリイソブチレンの各分子量は特に限定されるものではないが、良好な皮膚接着性やビソプロロールの充分な放出性を得るためには、第1のポリイソブチレンの粘度平均分子量は好ましくは1,800,000~5,500,000、より好ましくは2,000,000~5,000,000であり、かつ第2のポリイソブチレンの粘度平均分子量は好ましくは40,000~85,000、より好ましくは45,000~65,000である。第1のポリイソブチレンの粘度平均分子量が1,800,000未満であると、粘着剤層に必要な内部凝集力を付与し難くなるおそれがあり、他方、5,500,000を超えると、粘着剤層の皮膚接着性やタックが低下するおそれがある。また、第2のポリイソブチレンの粘度平均分子量が40,000未満であると、粘着剤層にベトツキ感が発現し、あるいは皮膚面を汚染するおそれがあり、他方、85,000を超えると粘着剤層の皮膚接着性やタックが低下するおそれがある。なお、第1および第2のポリイソブチレンは、それぞれの分子量分布の範囲内で2種以上を組み合わせて用いることができる。 The molecular weights of the first polyisobutylene and the second polyisobutylene are not particularly limited, but in order to obtain good skin adhesion and sufficient release of bisoprolol, The viscosity average molecular weight is preferably 1,800,000 to 5,500,000, more preferably 2,000,000 to 5,000,000, and the viscosity average molecular weight of the second polyisobutylene is preferably 40,000 000 to 85,000, more preferably 45,000 to 65,000. If the viscosity average molecular weight of the first polyisobutylene is less than 1,800,000, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer, and if it exceeds 5,500,000, There is a possibility that the adhesiveness and tackiness of the agent layer may be lowered. Further, if the viscosity average molecular weight of the second polyisobutylene is less than 40,000, the pressure-sensitive adhesive layer may feel sticky or may contaminate the skin surface, while if it exceeds 85,000, the pressure-sensitive adhesive. There is a risk that the skin adhesion and tack of the layer may be reduced. In addition, the 1st and 2nd polyisobutylene can be used in combination of 2 or more type within the range of each molecular weight distribution.
 なお、本明細書において、粘度平均分子量とは、ウベローデ粘度計のキャピラリーの20℃におけるフロータイムから、Schulz-Blaschke式(下記式(1))によりシュタウディンガーインデックス(J)を算出し、このJ値を用いて下式(2)により求められる値をいう。 In the present specification, the viscosity average molecular weight is a Staudinger index (J 0 ) calculated from the flow time at 20 ° C. of the capillary of the Ubbelohde viscometer by the Schulz-Blaschke equation (the following equation (1)), It refers to a value determined by the following equation (2) using the J 0 value.
 J=ηSP/c(1+0.31ηSP)(cm/g) (Schulz-Blaschke式) …(1)
  ηSP=t/t-1
  t :溶液のフロータイム (Hagenbach-Couette補正式による)
  t:溶媒のフロータイム (Hagenbach-Couette補正式による)
  c :溶液の濃度(g/cm
 J=3.06×10-2Mv0.65 … (2)
  Mv:粘度平均分子量
J 0 = η SP /c(1+0.31η SP ) (cm 3 / g) (Schulz-Blaschke equation) (1)
η SP = t / t 0 −1
t: Flow time of solution (according to Hagenbach-Couette correction formula)
t 0 : Flow time of solvent (according to Hagenbach-Couette correction formula)
c: Solution concentration (g / cm 3 )
J 0 = 3.06 × 10 −2 Mv 0.65 (2)
Mv: viscosity average molecular weight
 粘着剤層が分子量の異なる2種以上のポリイソブチレンを含有する場合、ポリイソブチレンの合計含有量は、粘着剤層の全重量に対して、好ましくは15重量%~60重量%、より好ましくは15重量%~55重量%である。ポリイソブチレンの合計含有量が15重量%未満であると、粘着剤層に必要な内部凝集力を付与し難くなるおそれがあり、他方、60重量%を超えると、粘着剤層の皮膚接着性やタックが低下するおそれがある。
 また、粘着剤層が分子量の異なる2種のポリイソブチレンを含有する場合、第1のポリイソブチレン(a)と、第2のポリイソブチレン(b)の配合重量比(a:b)は、好ましくは1:0.1~1:3、より好ましくは1:0.1~1:2.5、更に好ましくは1:0.3~1:2である。これら2種のポリイソブチレンのうち、第1のポリイソブチレン(a)に対する第2のポリイソブチレン(b)の配合重量比(b/a)が3を超えると、粘着剤層の内部凝集力の低下が大きくなるおそれがあり、他方、0.1未満であると、粘着剤層の皮膚接着力の低下が大きくなるおそれがある。
When the pressure-sensitive adhesive layer contains two or more types of polyisobutylene having different molecular weights, the total content of polyisobutylene is preferably 15% by weight to 60% by weight, more preferably 15% by weight with respect to the total weight of the pressure-sensitive adhesive layer. % By weight to 55% by weight. If the total content of polyisobutylene is less than 15% by weight, it may be difficult to impart the necessary internal cohesive force to the pressure-sensitive adhesive layer. On the other hand, if the total content exceeds 60% by weight, Tack may be reduced.
When the pressure-sensitive adhesive layer contains two types of polyisobutylene having different molecular weights, the blending weight ratio (a: b) of the first polyisobutylene (a) and the second polyisobutylene (b) is preferably The ratio is 1: 0.1 to 1: 3, more preferably 1: 0.1 to 1: 2.5, and still more preferably 1: 0.3 to 1: 2. Of these two types of polyisobutylene, if the blending weight ratio (b / a) of the second polyisobutylene (b) to the first polyisobutylene (a) exceeds 3, the internal cohesive force of the pressure-sensitive adhesive layer decreases. On the other hand, if it is less than 0.1, the skin adhesive force of the pressure-sensitive adhesive layer may be greatly reduced.
 粘着剤層に含有させる粘着剤として、ゴム系粘着剤を使用する場合、貼付製剤の分野で公知のタッキファイヤーを適宜選択して含有させることが好ましい。かかるタッキファイヤーとしては、例えば、石油系樹脂(例えば、芳香族系石油樹脂、脂肪族系石油樹脂)、テルペン系樹脂、ロジン系樹脂、クマロンインデン樹脂、スチレン系樹脂(例えば、スチレン樹脂、α-メチルスチレン樹脂)、水素添加石油樹脂(例えば、脂環族飽和炭化水素樹脂)等が挙げられる。中でも、脂環族飽和炭化水素樹脂が、ビソプロロールの保存安定性が良好になるため好適である。
 タッキファイヤーは、1種または2種以上を組み合わせて用いることができ、2種以上を組み合わせて使用する場合には、例えば、樹脂の種類や軟化点の異なる樹脂を組み合わせてもよい。
 タッキファイヤーの含有量は、粘着剤層の全重量に対して、好ましくは10重量%~55重量%、より好ましくは10重量%~50重量%、特に好ましくは10重量%~45重量%である。タッキファイヤーの含有量が10重量%未満であると、タックおよび凝集力が乏しくなる場合があり、他方55重量%を超えると、粘着剤層が固くなり、皮膚接着性が低下する傾向にある。
 なお、タッキファイヤーの軟化点は、好ましくは90℃~150℃、より好ましくは95℃~145℃である。軟化点が90℃~150℃であると、粘着剤層の各含有成分との相溶性が良好で、均一に混合しやすくなる傾向にある。なお、本発明における軟化点は環球法によって測定される値である。
When using a rubber-based pressure-sensitive adhesive as the pressure-sensitive adhesive contained in the pressure-sensitive adhesive layer, it is preferable to appropriately select and contain a tackifier known in the field of patch preparations. Examples of such tackifiers include petroleum resins (for example, aromatic petroleum resins and aliphatic petroleum resins), terpene resins, rosin resins, coumarone indene resins, styrene resins (for example, styrene resins, α -Methylstyrene resin), hydrogenated petroleum resin (for example, alicyclic saturated hydrocarbon resin) and the like. Among these, alicyclic saturated hydrocarbon resins are preferable because the storage stability of bisoprolol is improved.
The tackifier can be used singly or in combination of two or more. When two or more types are used in combination, for example, resins having different types and softening points may be combined.
The content of the tackifier is preferably 10% to 55% by weight, more preferably 10% to 50% by weight, particularly preferably 10% to 45% by weight, based on the total weight of the pressure-sensitive adhesive layer. . If the content of the tackifier is less than 10% by weight, tack and cohesive force may be poor. On the other hand, if the content exceeds 55% by weight, the pressure-sensitive adhesive layer becomes hard and the skin adhesiveness tends to be lowered.
The softening point of the tackifier is preferably 90 ° C to 150 ° C, more preferably 95 ° C to 145 ° C. When the softening point is 90 ° C. to 150 ° C., the compatibility with each component contained in the pressure-sensitive adhesive layer is good, and it tends to be easy to mix uniformly. The softening point in the present invention is a value measured by the ring and ball method.
 粘着剤層には、常温(25℃)で流動性を有する有機液状成分を含有させてもよい。有機液状成分としては、薬物であるビソプロロール以外に添加される液状の有機成分であって、粘着剤層の他の構成成分(例えば、粘着剤、タッキファイヤー)と相溶可能なものであれば特に限定されるものではない。有機液状成分としては、ビソプロロールの吸収促進およびビソプロロールの粘着剤層への溶解性向上に大きく寄与する点から、脂肪酸アルキルエステル、長鎖アルコールが好適に使用される。有機液状成分は、1種単独でまたは2種以上を組み合わせて用いてもよい。 The pressure-sensitive adhesive layer may contain an organic liquid component having fluidity at room temperature (25 ° C.). The organic liquid component is a liquid organic component that is added in addition to the drug bisoprolol and is particularly compatible with other components of the pressure-sensitive adhesive layer (for example, pressure-sensitive adhesive, tackifier). It is not limited. As the organic liquid component, fatty acid alkyl esters and long-chain alcohols are preferably used because they greatly contribute to promoting absorption of bisoprolol and improving the solubility of bisoprolol in the pressure-sensitive adhesive layer. You may use an organic liquid component individually by 1 type or in combination of 2 or more types.
 上記脂肪酸アルキルエステルとしては、例えば、炭素数12~16、好ましくは炭素数12~14の高級脂肪酸と、炭素数1~4の低級1価アルコールとから形成される脂肪酸アルキルエステルが挙げられる。好ましい高級脂肪酸としては、ラウリン酸(炭素数12)、ミリスチン酸(炭素数14)、パルミチン酸(炭素数16)が挙げられ、ミリスチン酸がさらに好ましい。前記1価アルコールとしては、メチルアルコール、エチルアルコール、プロピルアルコール、イソプロピルアルコール、ブチルアルコール等が挙げられ、好ましくはイソプロピルアルコールである。従って、脂肪酸アルキルエステルとしてはミリスチン酸イソプロピルが最も好ましく、該化合物を用いることでビソプロロールの吸収促進、溶解性向上および薬物利用率を高水準で達成することができる。 Examples of the fatty acid alkyl ester include fatty acid alkyl esters formed from higher fatty acids having 12 to 16 carbon atoms, preferably 12 to 14 carbon atoms, and lower monohydric alcohols having 1 to 4 carbon atoms. Preferred higher fatty acids include lauric acid (carbon number 12), myristic acid (carbon number 14), and palmitic acid (carbon number 16), and myristic acid is more preferable. Examples of the monohydric alcohol include methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol, butyl alcohol, and the like, preferably isopropyl alcohol. Therefore, isopropyl myristate is most preferable as the fatty acid alkyl ester, and by using this compound, absorption enhancement of bisoprolol, improvement in solubility, and drug utilization can be achieved at a high level.
 また、上記長鎖アルコールとしては、例えば炭素数12~28、好ましくは炭素数12~24の飽和または不飽和の長鎖アルコールが挙げられ、保存安定性の面から飽和の長鎖アルコールが好適に使用される。また、上記長鎖アルコールとしては、直鎖または分岐鎖長鎖アルコールが挙げられ、これらは混合して使用することができる。かかる直鎖アルコールとしては、1-ドデカノール、1-テトラデカノール、1-ヘキサデカノール、ステアリルアルコール等が挙げられ、中でも1-ドデカノールがポリイソブチレンとの相溶性や、ビソプロロールの安定化に優れる点で好ましい。また、ポリイソブチレンとの相溶性が得難い場合には、例えば炭素数16~28、好ましくは炭素数18~24の分岐鎖長鎖アルコールを用いることができる。具体的には、2-ヘキシルデカノール、イソステアリルアルコール、2-オクチルドデカノール、2-デシルテトラデカノール等が挙げられ、中でも2-オクチルドデカノールがポリイソブチレンとの相溶性に優れるとともに、ビソプロロールの溶解性を向上させることができる点で好ましい。 Examples of the long-chain alcohol include saturated or unsaturated long-chain alcohols having 12 to 28 carbon atoms, preferably 12 to 24 carbon atoms, and saturated long-chain alcohols are preferable from the viewpoint of storage stability. used. Moreover, as said long chain alcohol, a linear or branched long chain alcohol is mentioned, These can be mixed and used. Examples of such linear alcohols include 1-dodecanol, 1-tetradecanol, 1-hexadecanol, stearyl alcohol, etc. Among them, 1-dodecanol is excellent in compatibility with polyisobutylene and stability of bisoprolol. Is preferable. When compatibility with polyisobutylene is difficult to obtain, for example, a branched long-chain alcohol having 16 to 28 carbon atoms, preferably 18 to 24 carbon atoms can be used. Specific examples include 2-hexyldecanol, isostearyl alcohol, 2-octyldodecanol, and 2-decyltetradecanol. Among them, 2-octyldodecanol is excellent in compatibility with polyisobutylene and dissolves bisoprolol. It is preferable at the point which can improve property.
 有機液状成分として、脂肪酸アルキルエステルを単独で用いても上述した効果が充分に得られるが、脂肪酸アルキルエステルおよび長鎖アルコールを組み合わせて用いると、ビソプロロールの透過性および溶解性、更には粘着剤層の皮膚接着性が一層向上する点で好ましい。脂肪酸アルキルエステル(c)と長鎖アルコール(d)の配合重量比(c:d)は、好ましくは1:0.01~1:0.5、より好ましくは1:0.01~1:0.4、更に好ましくは1:0.05~1:0.4である。これら2種の有機液状成分中、脂肪酸アルキルエステル(c)に対する長鎖アルコール(d)の配合重量比(d/c)が0.01以上であると、ビソプロロールの透過性および溶解性、ならびに粘着剤層の皮膚接着性の向上が見られるが、0.5を超えると、脂肪酸アルキルエステル(c)の配合割合が相対的に減少するため、高レベルで経皮吸収促進を持続させることが困難になるおそれがある。 Even if the fatty acid alkyl ester is used alone as the organic liquid component, the above-described effects can be sufficiently obtained. However, when the fatty acid alkyl ester and the long-chain alcohol are used in combination, the permeability and solubility of bisoprolol, and further the pressure-sensitive adhesive layer It is preferable in terms of further improving the skin adhesiveness. The blending weight ratio (c: d) of the fatty acid alkyl ester (c) and the long-chain alcohol (d) is preferably 1: 0.01 to 1: 0.5, more preferably 1: 0.01 to 1: 0. .4, more preferably 1: 0.05 to 1: 0.4. In these two kinds of organic liquid components, when the blending weight ratio (d / c) of the long-chain alcohol (d) to the fatty acid alkyl ester (c) is 0.01 or more, the permeability and solubility of bisoprolol, and adhesion Improvement of the skin adhesion of the preparation layer can be seen, but if it exceeds 0.5, the blending ratio of the fatty acid alkyl ester (c) is relatively reduced, so it is difficult to sustain the promotion of percutaneous absorption at a high level. There is a risk of becoming.
 上記のように、有機液状成分は透過促進剤として有効に作用する場合が多く、その際には有機液状成分の含有量を増量することにより、ビソプロロールの皮膚透過性が向上する。すなわち、粘着剤層に有機液状成分を多量に含有させることで、皮膚透過性がより高く、また皮膚透過性を制御し易い組成となるため、貼付製剤として理想的な粘着剤の組成といえる。また、粘着剤層に有機液状成分を含有させることで、粘着剤層に適度な柔軟性および皮膚接着性を付与することができる。 As described above, the organic liquid component often acts effectively as a permeation enhancer, and in that case, the skin permeability of bisoprolol is improved by increasing the content of the organic liquid component. That is, by containing a large amount of an organic liquid component in the pressure-sensitive adhesive layer, the composition has a higher skin permeability and can easily control the skin permeability. Therefore, it can be said to be an ideal pressure-sensitive adhesive composition as a patch preparation. Moreover, moderate softness | flexibility and skin adhesiveness can be provided to an adhesive layer by containing an organic liquid component in an adhesive layer.
 有機液状成分を使用する場合、粘着剤層からの有機液状成分のはみ出しを防止するため、有機液状成分の含有量は、粘着剤層の全重量に対して好ましくは5重量%~70重量%、より好ましくは10重量%~65重量%、さらに好ましくは20重量%~50重量%である。 When the organic liquid component is used, in order to prevent the organic liquid component from protruding from the pressure-sensitive adhesive layer, the content of the organic liquid component is preferably 5% by weight to 70% by weight with respect to the total weight of the pressure-sensitive adhesive layer. More preferably, it is 10 wt% to 65 wt%, and further preferably 20 wt% to 50 wt%.
 本発明の貼付製剤においては、粘着剤層に上記以外の成分を適宜加えてもよい。例えば、粘着剤層中でのビソプロロールの溶解性を更に高め、より良好な皮膚低刺激性を得るためには、必要に応じて粘着剤層中に上記以外の液状またはペースト状の有機成分からなる溶解助剤を配合することができる。かかる溶解助剤は、粘着剤との相溶性に優れており、ビソプロロールを充分に溶解し、粘着剤層からビソプロロールが滲み出す(ブリード)おそれが少なく、粘着特性や薬物放出性に悪影響を及ぼさないものであればよい。具体的には、オレイン酸、ミリスチン酸、カプリン酸等の脂肪酸、アジピン酸、セバシン酸等のジカルボン酸等の有機酸と、エタノール、2-プロパノール等のアルコール類とのエステル類;グリセリン、プロピレングリコール等の多価アルコールやそれらのジ、トリエステル類;多価アルコールと、トリアセチン等の有機酸とのエステル類;ポリエチレングリコール、ポリプロピレングリコール、ポリオキシエチレン硬化ヒマシ油等のポリエーテル類;その他クロタミトン等が挙げられる。 In the patch preparation of the present invention, components other than those described above may be appropriately added to the adhesive layer. For example, in order to further enhance the solubility of bisoprolol in the pressure-sensitive adhesive layer and to obtain better skin hypoallergenicity, the pressure-sensitive adhesive layer comprises a liquid or paste-like organic component other than the above as necessary. A dissolution aid can be blended. Such a solubilizing agent has excellent compatibility with the pressure-sensitive adhesive, sufficiently dissolves bisoprolol, has a low risk of bleeding out of the pressure-sensitive adhesive layer (bleed), and does not adversely affect the adhesive properties and drug release properties. Anything is acceptable. Specifically, esters of fatty acids such as oleic acid, myristic acid and capric acid, organic acids such as dicarboxylic acids such as adipic acid and sebacic acid, and alcohols such as ethanol and 2-propanol; glycerin and propylene glycol Polyhydric alcohols such as diesters and triesters thereof; Esters of polyhydric alcohols and organic acids such as triacetin; Polyethers such as polyethylene glycol, polypropylene glycol, polyoxyethylene hydrogenated castor oil; Other crotamitons, etc. Is mentioned.
 また、粘着剤層の凝集力を向上させるため、所望により、粘着剤層に適当な充填剤を含有させることができる。このような充填剤としては特に限定されないが、シリカ、酸化チタン、酸化亜鉛、酸化マグネシウム、酸化鉄、水酸化アルミニウム、タルク、カオリン、ベントナイト、硫酸バリウム、炭酸カルシウム等の無機微粒子、乳糖、カーボンブラック、ポリビニルピロリドン、ポリエステル、ポリオレフィン、ポリウレタン、ポリアミド、セルロース類、アクリル樹脂等の有機微粒子、更にはポリエステル、ポリオレフィン、ポリウレタン、ポリアミド、セルロース類、アクリル樹脂、ガラス等の繊維が挙げられる。 Moreover, in order to improve the cohesive force of the pressure-sensitive adhesive layer, an appropriate filler can be contained in the pressure-sensitive adhesive layer as desired. Such fillers are not particularly limited, but include silica, titanium oxide, zinc oxide, magnesium oxide, iron oxide, aluminum hydroxide, talc, kaolin, bentonite, barium sulfate, calcium carbonate and other inorganic fine particles, lactose, carbon black And organic fine particles such as polyvinylpyrrolidone, polyester, polyolefin, polyurethane, polyamide, cellulose, and acrylic resin, and fibers such as polyester, polyolefin, polyurethane, polyamide, cellulose, acrylic resin, and glass.
 さらに、所望により、粘着剤層に適当な軟化剤を含有させることで、粘着剤層に適度な皮膚接着力やタックを付与することができる。このような軟化剤としては特に限定されないが、液状ポリブテン、液状ポリイソプレンなどの液状ゴムや、有機液状成分の中でも、流動パラフィン、スクワラン、スクワレンなどの液状炭化水素等が挙げられる。さらに、所望によりカバーテープなどを本発明の貼付製剤の一部や全面を覆うように貼付して皮膚接着性を補強し、皮膚への密着性を補ってもよい。 Furthermore, if desired, an appropriate softening agent or tack can be imparted to the pressure-sensitive adhesive layer by adding an appropriate softening agent to the pressure-sensitive adhesive layer. The softening agent is not particularly limited, and examples thereof include liquid rubbers such as liquid polybutene and liquid polyisoprene, and liquid hydrocarbons such as liquid paraffin, squalane and squalene among organic liquid components. Further, if desired, a cover tape or the like may be applied so as to cover a part or the entire surface of the patch preparation of the present invention to reinforce the skin adhesiveness and supplement the adhesion to the skin.
 本発明において、粘着剤として第1のポリイソブチレンを用いる場合、多量の有機液状成分を含有させることが可能になり、その結果、有機液状成分による薬物の吸収促進効果と溶解性向上効果とを充分に得ることができる。これにより、凝集力の低下を抑制し、糊残り等のない貼付製剤とすることが可能になる。さらに、タッキファイヤーについても、上述した軟化点の温度範囲の中でより高いものを用いることで、凝集力の向上だけでなく、皮膚接着性の向上も同時に達成することが可能になる。なお、粘着剤層の厚みは、通常10μm~300μm、好ましくは10μm~250μm、さらに好ましくは15μm~250μmである。 In the present invention, when the first polyisobutylene is used as the pressure-sensitive adhesive, it becomes possible to contain a large amount of an organic liquid component. As a result, the effect of promoting the absorption of the drug by the organic liquid component and the effect of improving the solubility are sufficient. Can get to. As a result, it is possible to suppress a reduction in cohesive force and to obtain a patch preparation with no adhesive residue or the like. Further, by using a tackifier that is higher in the temperature range of the softening point described above, not only the cohesive force but also the skin adhesion can be improved at the same time. The thickness of the pressure-sensitive adhesive layer is usually 10 μm to 300 μm, preferably 10 μm to 250 μm, and more preferably 15 μm to 250 μm.
 ビソプロロールの経時安定性を向上させるためには、粘着剤層の含水率は10,000ppm以下であり、好ましくは200ppm~10,000ppmである。
 粘着剤層の含水率の好ましい範囲の下限値は、貼付製剤の製造時における水分制御の可能性の観点から、例えば、200ppm、300ppm、400ppm、500ppm、600ppm、700ppm、800ppm、900ppm、1,000ppm、1,500ppm、2,000ppm、2,500ppm、3,000ppm、3,500ppmまたは4,000ppmであり得る。粘着剤層の含水率の好ましい範囲の上限値は、ビソプロロールの安定性の観点から、例えば、10,000ppm、9,500ppm、9,000ppm、8,500ppm、8,000ppm、7,500ppm、7,000ppm、6,500ppm、6,000ppm、5,500ppmまたは5,000ppmであり得る。ここで、粘着剤層の含水率とは、カールフィッシャー電量滴定法により測定される、粘着剤層中に含まれる水の重量の割合(粘着剤層の総重量に対する水の重量の割合)を意味し、本明細書においては、後述する実施例に記載の測定条件で測定される値である。
In order to improve the temporal stability of bisoprolol, the moisture content of the pressure-sensitive adhesive layer is 10,000 ppm or less, preferably 200 ppm to 10,000 ppm.
The lower limit value of the preferable range of the moisture content of the pressure-sensitive adhesive layer is, for example, 200 ppm, 300 ppm, 400 ppm, 500 ppm, 600 ppm, 700 ppm, 800 ppm, 900 ppm, 1,000 ppm from the viewpoint of the possibility of moisture control during the manufacture of the patch preparation. 1,500 ppm, 2,000 ppm, 2,500 ppm, 3,000 ppm, 3,500 ppm or 4,000 ppm. From the viewpoint of the stability of bisoprolol, the upper limit value of the preferable moisture content of the pressure-sensitive adhesive layer is, for example, 10,000 ppm, 9,500 ppm, 9,000 ppm, 8,500 ppm, 8,000 ppm, 7,500 ppm, 7, 000 ppm, 6,500 ppm, 6,000 ppm, 5,500 ppm or 5,000 ppm. Here, the moisture content of the pressure-sensitive adhesive layer means the ratio of the weight of water contained in the pressure-sensitive adhesive layer (the ratio of the weight of water to the total weight of the pressure-sensitive adhesive layer) measured by the Karl Fischer coulometric titration method. In this specification, it is a value measured under the measurement conditions described in the examples described later.
 貼付製剤の粘着剤層の含水率は、外部環境(雰囲気)の相対湿度に依存して変動し、時間の経過とともに、その温湿度における平衡含水率に収束する。すなわち、外部環境(雰囲気)の相対湿度が高いと、粘着剤層が水分を吸収、吸着するなどして、粘着剤層の含水率が上昇する。逆に、外部環境(雰囲気)の相対湿度が低いと、粘着剤層への水分の吸着が抑制されるとともに粘着剤層から水分が放出されるなどして、粘着剤層の含水率が減少する。従って、外部環境(雰囲気)の温度および/または相対湿度を調整することにより、粘着剤層の含水率を制御することができる。なお、外部環境(雰囲気)の温度および相対湿度の調整は、公知の空調設備で適宜行うことができる。 The moisture content of the adhesive layer of the patch preparation varies depending on the relative humidity of the external environment (atmosphere) and converges to the equilibrium moisture content at that temperature and humidity with the passage of time. That is, when the relative humidity in the external environment (atmosphere) is high, the pressure-sensitive adhesive layer absorbs and adsorbs moisture, and the moisture content of the pressure-sensitive adhesive layer increases. Conversely, when the relative humidity of the external environment (atmosphere) is low, the moisture content of the pressure-sensitive adhesive layer decreases due to the suppression of moisture adsorption to the pressure-sensitive adhesive layer and the release of moisture from the pressure-sensitive adhesive layer. . Therefore, the moisture content of the pressure-sensitive adhesive layer can be controlled by adjusting the temperature and / or relative humidity of the external environment (atmosphere). In addition, adjustment of the temperature and relative humidity of the external environment (atmosphere) can be appropriately performed with a known air conditioner.
 例えば、ビソプロロール含有貼付製剤の製造工程において、打ち抜き加工や包装段階の雰囲気を、温度=20±10℃、および相対湿度=30±10%に保ち、このような環境下で、貼付製剤を30分~48時間保持することにより、粘着剤層の含水率を上記範囲に制御することができる。 For example, in the manufacturing process of a bisoprolol-containing patch preparation, the atmosphere of the punching process and the packaging stage is maintained at a temperature of 20 ± 10 ° C. and a relative humidity of 30 ± 10%. By holding for ˜48 hours, the water content of the pressure-sensitive adhesive layer can be controlled within the above range.
 本発明の貼付製剤においては、使用時まで粘着剤層の粘着面を保護するために、粘着面に剥離ライナーが積層されてもよい。かかる剥離ライナーとしては、特に限定されるものではないが、例えば、粘着剤層との接触面にシリコーン樹脂、フッ素樹脂等を塗布することによって易剥離処理が施された、ポリエステル、ポリ塩化ビニル、ポリ塩化ビニリデン、ポリエチレンテレフタレート等のフィルム、上質紙、グラシン紙等の紙、または上質紙もしくはグラシン紙等とポリオレフィンとのラミネートフィルム等が用いられる。剥離ライナーの厚みは、好ましくは10μm~200μm、より好ましくは25μm~150μmである。 In the adhesive preparation of the present invention, a release liner may be laminated on the adhesive surface in order to protect the adhesive surface of the adhesive layer until use. The release liner is not particularly limited. For example, polyester, polyvinyl chloride, which has been subjected to an easy release treatment by applying a silicone resin, a fluorine resin, or the like to the contact surface with the pressure-sensitive adhesive layer, A film such as polyvinylidene chloride and polyethylene terephthalate, paper such as high-quality paper and glassine paper, or a laminate film of high-quality paper or glassine paper and polyolefin is used. The thickness of the release liner is preferably 10 μm to 200 μm, more preferably 25 μm to 150 μm.
 本発明の目的には、剥離ライナーとしては、バリアー性、価格等の点から、ポリエステル(特に、ポリエチレンテレフタレート)樹脂からなるものが好ましい。さらに、この場合、取り扱い性の点から、25μm~100μm程度の厚みを有するものが好ましい。 For the purpose of the present invention, the release liner is preferably made of a polyester (particularly, polyethylene terephthalate) resin from the viewpoint of barrier properties, cost, and the like. Further, in this case, those having a thickness of about 25 μm to 100 μm are preferable from the viewpoint of handleability.
 本発明の貼付製剤の形状としては特に限定されず、例えば、テープ状、シート状を含む。
 本発明の貼付製剤は、例えば、粘着剤、ビソプロロール、必要によりタッキファイヤー、有機液状成分等を含む粘着剤組成物をトルエン等の適当な溶媒に溶解し、得られた溶液を剥離ライナー上に塗布、乾燥して粘着剤層を形成し、そして粘着剤層上に支持体を積層することにより製造することができる。また、例えば、上記粘着剤溶液を支持体に直接塗布、乾燥して支持体上に粘着剤層を形成して製造することができる。なお、粘着剤層を形成する際に粘着剤組成物の溶液を一度に厚く塗布すると均一に乾燥することが困難な場合があるため、粘着剤層の厚みを充分なものにするために、2度以上に分けて塗工してもよい。
The shape of the patch preparation of the present invention is not particularly limited and includes, for example, a tape shape and a sheet shape.
The adhesive preparation of the present invention is prepared by, for example, dissolving a pressure-sensitive adhesive composition containing a pressure-sensitive adhesive, bisoprolol, if necessary, a tackifier, an organic liquid component, etc. in an appropriate solvent such as toluene, and applying the obtained solution onto a release liner. It can be produced by drying, forming a pressure-sensitive adhesive layer, and laminating a support on the pressure-sensitive adhesive layer. In addition, for example, the pressure-sensitive adhesive solution can be directly applied to a support and dried to form a pressure-sensitive adhesive layer on the support. In addition, when forming the pressure-sensitive adhesive layer, it may be difficult to uniformly dry the solution of the pressure-sensitive adhesive composition when applied thickly at one time. You may divide it more than once.
 なお、貼付製剤側面からの粘着剤層の含有成分の滲み出しを防ぐために、貼付製剤の周辺部を加圧し、周辺部における粘着剤層の厚みの低減した形状とすることもできる。 In addition, in order to prevent exudation of the components contained in the adhesive layer from the side of the adhesive preparation, it is possible to pressurize the peripheral part of the adhesive preparation so that the thickness of the adhesive layer in the peripheral part is reduced.
 本発明の貼付製剤は、使用時まで耐透湿性袋体に封入され、包装体として保存または運搬することが好ましい。かかる包装体の形成方法としては、例えば、1枚の貼付製剤、あるいは数枚重ねた貼付製剤を耐透湿性袋体を構成する包装材により包装し、その周辺をヒートシールして密封する方法が挙げられる。前記包装材としては、例えば、シート状またはフィルム状のものが挙げられ、粘着剤層の含水率の制御、および包装の容易さや気密性の観点から、水分不透過性を示し、かつヒートシール可能なものが望ましい。具体的には、ポリエチレン、アイオノマー樹脂、エチレン-酢酸ビニル共重合体、エチレン-ビニルアルコール共重合体、ポリアクリロニトリル系共重合体、ポリビニルアルコール系共重合体等のヒートシール性を有するプラスチックシートに、ポリエステルフィルムや金属箔等のガスまたは水分不透過性フィルムを積層した包装材を用いることが好ましい。ガスまたは水分不透過性フィルムを用いることで、包装体内に乾燥剤を封入したり、または包装材自体に乾燥剤を含有させる必要なく、粘着剤層の水分含量を上記のように制御することができる。
 上記包装材としては、通常、厚さ10μm~200μmのものが用いられる。
The patch preparation of the present invention is preferably enclosed in a moisture-permeable bag until use and stored or transported as a package. As a method for forming such a package, for example, there is a method in which a single patch preparation or a plurality of patch preparations are packaged with a packaging material constituting a moisture-permeable bag body and the periphery is sealed by heat sealing. Can be mentioned. Examples of the packaging material include a sheet-like or film-like material. From the viewpoints of controlling the moisture content of the pressure-sensitive adhesive layer, ease of packaging, and airtightness, the packaging material exhibits moisture impermeability and can be heat-sealed. Is desirable. Specifically, a plastic sheet having heat sealing properties such as polyethylene, ionomer resin, ethylene-vinyl acetate copolymer, ethylene-vinyl alcohol copolymer, polyacrylonitrile copolymer, polyvinyl alcohol copolymer, It is preferable to use a packaging material in which a gas or moisture impermeable film such as a polyester film or a metal foil is laminated. By using a gas or moisture impermeable film, the moisture content of the pressure-sensitive adhesive layer can be controlled as described above without having to enclose the desiccant in the package or containing the desiccant in the packaging material itself. it can.
As the packaging material, one having a thickness of 10 μm to 200 μm is usually used.
 なお、上記包装材としては、最内層(ビソプロロール含有貼付製剤を耐透湿性袋体に封入した際に、ビソプロロール含有貼付製剤の近位側に位置する層)にバリアー性の高いアクリロニトリル系樹脂を用いたものがより好ましい。アクリロニトリル系樹脂は、アクリロニトリル系樹脂層の性状均一性の観点から、アクリロニトリルを主たる構造単位とする共重合体であることが好ましく、当該共重合体は、構造単位として、少なくとも、アクリロニトリルと、ブタジエン等のゴム成分、および/または、アルキル基の炭素数が1~6の(メタ)アクリル酸アルキルエステルを含む共重合体であることが好ましい。また、当該共重合体において、アクリロニトリルの含有量は50重量%~90重量%であることが好ましく、特に好ましい共重合体は、アクリロニトリル50重量%~90重量%、ブタジエン等のゴム成分2重量%~12重量%、アルキル基の炭素数が1~6である(メタ)アクリル酸アルキルエステル8重量%~38重量%の組成を有する単量体成分を共重合させてなる共重合体である。また、当該共重合体の共重合形態は、ランダム共重合でも、ブロック共重合でも、グラフト共重合でもよいが、生理活性成分に対する非吸着性に優れるポリアクリロニトリルの特徴と、衝撃吸収性に優れるゴム成分の特徴を効率的に併せ持ち得るグラフト共重合形態が好ましく、かかる特徴を阻害しない程度であればランダム共重合やブロック共重合が適宜加わってもよい。 As the packaging material, an acrylonitrile-based resin having a high barrier property is used for the innermost layer (the layer located on the proximal side of the bisoprolol-containing patch preparation when the bisoprolol-containing patch preparation is sealed in a moisture-permeable bag). More preferred. The acrylonitrile-based resin is preferably a copolymer having acrylonitrile as a main structural unit from the viewpoint of uniformity of properties of the acrylonitrile-based resin layer, and the copolymer has at least acrylonitrile, butadiene, etc. as the structural unit. The rubber component and / or a copolymer containing an alkyl (meth) acrylic acid alkyl ester having 1 to 6 carbon atoms is preferable. In the copolymer, the content of acrylonitrile is preferably 50% by weight to 90% by weight, and particularly preferable copolymer is 50% by weight to 90% by weight of acrylonitrile, and 2% by weight of a rubber component such as butadiene. It is a copolymer obtained by copolymerizing a monomer component having a composition of ˜12 wt% and (meth) acrylic acid alkyl ester having an alkyl group having 1 to 6 carbon atoms of 8 wt% to 38 wt%. The copolymer may be in random copolymerization, block copolymerization, or graft copolymerization, but is characterized by the characteristics of polyacrylonitrile having excellent non-adsorptivity to physiologically active components and rubber having excellent shock absorption. A graft copolymerization form capable of efficiently having the characteristics of the components is preferable, and random copolymerization or block copolymerization may be appropriately added as long as the characteristics are not inhibited.
 なお、本発明におけるアクリロニトリル系樹脂の組成分析は、以下の方法によるものである。
 すなわち、包装材からアクリロニトリル系樹脂層を削り出した試料について、CHN元素分析を行い、窒素含有量によりアクリロニトリルの含有量を算出する。さらにH-NMRおよび13C-NMR(重ジメチルスルホキシド(DMSO)中、80℃)のスペクトルにより、ゴム成分およびアルキル基の炭素数が1~6である(メタ)アクリル酸アルキルエステル成分の分子構造と重量比を求め、前記3成分の重量比を求める。
In addition, the composition analysis of the acrylonitrile-type resin in this invention is based on the following method.
That is, the CHN elemental analysis is performed on the sample obtained by scraping the acrylonitrile-based resin layer from the packaging material, and the acrylonitrile content is calculated from the nitrogen content. Further, according to the spectra of 1 H-NMR and 13 C-NMR (in heavy dimethyl sulfoxide (DMSO), 80 ° C.), the rubber component and the molecule of the (meth) acrylic acid alkyl ester component in which the alkyl group has 1 to 6 carbon atoms The structure and weight ratio are determined, and the weight ratio of the three components is determined.
 アクリロニトリル系樹脂層の厚みは、貼付製剤の種類等に応じて適宜設定され、特に限定はされないが、貼付製剤中の生理活性成分に対する非透過性および非吸着性が良好に発揮され、かつ、水分不透過性を有しつつ、貼付製剤の包装材としての適度な柔軟性と剛性を確保する観点から、5μm~100μmが好ましく、5μm~80μmがより好ましく、5μm~50μmが最も好ましい。 The thickness of the acrylonitrile-based resin layer is appropriately set according to the type of the patch preparation, and is not particularly limited. However, the non-permeability and non-adsorption property to the physiologically active ingredient in the patch preparation are satisfactorily exhibited, and moisture From the viewpoint of ensuring appropriate flexibility and rigidity as a packaging material for a patch preparation while having impermeability, it is preferably 5 μm to 100 μm, more preferably 5 μm to 80 μm, and most preferably 5 μm to 50 μm.
 さらに、貼付製剤の側面から粘着成分の流れ出し等が起こった場合、包装体からの取り出し等の取り扱い性の悪化が懸念されるため、包装材にエンボス加工を施したり、前述の剥離ライナー部分を貼付製剤本体より若干大きくするドライエッジ加工や、接触面積が小さくなるように加工するブリスター成型等、包装形態を工夫することが好ましい。
 本発明の貼付製剤は、使用直前に上記包装体を破る等して貼付製剤を取り出し、剥離ライナーを剥がして露出した粘着面を皮膚面に貼付して使用することができる。
In addition, if the adhesive component flows out from the side of the patch preparation, there is a concern that the handling properties such as removal from the package may deteriorate, so embossing may be applied to the packaging material or the aforementioned release liner part may be applied. It is preferable to devise packaging forms such as dry edge processing that is slightly larger than the preparation body, or blister molding that is processed so that the contact area is small.
The patch preparation of the present invention can be used by taking out the patch preparation by tearing the above-mentioned package immediately before use, etc., peeling off the release liner and sticking the exposed adhesive surface to the skin surface.
 本発明の貼付製剤の用法は、患者の年齢、体重、症状等により異なる。
 本発明の貼付製剤の貼付面積は、上記したビソプロロールのヒト皮膚に対する透過速度の最大値を採用しつつ、有効量のビソプロロールの投与を達成するために考慮することができる。貼付製剤の貼付面積は、好ましくは3cm~50cm、より好ましくは3cm~48cm、更に好ましくは4cm~45cmである。
 貼付製剤の貼付面積が3cmより小さいと、貼付操作が困難となるおそれがあり、50cmより大きいと貼付時に患者にストレスを与えるおそれがある。薬効を強く必要とする場合には2枚以上を同時に貼付することも可能である。
The usage of the patch preparation of the present invention varies depending on the age, weight, symptoms, etc. of the patient.
The application area of the patch preparation of the present invention can be considered in order to achieve administration of an effective amount of bisoprolol while adopting the maximum value of the permeation rate of bisoprolol described above to human skin. The patch area of the patch preparation is preferably 3 cm 2 to 50 cm 2 , more preferably 3 cm 2 to 48 cm 2 , still more preferably 4 cm 2 to 45 cm 2 .
If the application area of the patch preparation is smaller than 3 cm 2 , the application operation may be difficult, and if it is larger than 50 cm 2 , the patient may be stressed at the time of application. When a strong medicinal effect is required, two or more sheets can be attached simultaneously.
 本発明のビソプロロール含有貼付製剤では、皮膚貼付直後から24時間経過までのビソプロロール放出速度の最大値を30μg/cm/時間以下とし、かつ皮膚貼付後24時間経過時におけるビソプロロール放出速度を10μg/cm/時間以下とするように制御される。 In the bisoprolol-containing patch preparation of the present invention, the maximum value of bisoprolol release rate immediately after skin application until 24 hours is 30 μg / cm 2 / hour or less, and the bisoprolol release rate after 24 hours after skin application is 10 μg / cm. 2 / hour or less.
 以下に実施例により本発明をさらに詳細に説明するが、本発明はこれらに限定されるものではない。後記において「部」あるいは「%」とあるのは、「重量部」あるいは「重量%」を意味する。 Hereinafter, the present invention will be described in more detail with reference to examples, but the present invention is not limited thereto. In the following description, “part” or “%” means “part by weight” or “% by weight”.
 [実施例1]
 高分子量ポリイソブチレン(粘度平均分子量=4,000,000)15.1部、中分子量ポリイソブチレン(粘度平均分子量=55,000)26.1部、脂環族飽和炭化水素樹脂(タッキファイヤー)27.4部、ミリスチン酸イソプロピル(有機液状成分)30.0部、ビソプロロール(フリー体)1.4部をトルエンに混合し、粘着剤組成物の粘稠トルエン溶液を調製した。得られた溶液を、ポリエチレンテレフタレート(PET)製剥離ライナー(厚さ75μm)上に、乾燥後の厚みが160μmとなるように塗布し、これを熱風循環式乾燥機中にて100℃で5分間乾燥して粘着剤層を形成した。
 この粘着剤層を、厚さ2μmのPET製フィルムとPET製不織布(目付量=12g/m)との積層フィルムである支持体の不織布側に貼り合わせ、36cm(6cm×6cm)の大きさに打ち抜いた後、貼付製剤の周辺部を加圧(4.9MPa)してビソプロロール含有貼付製剤を得た。
 ビソプロロール含有貼付製剤の製造工程において、上記打ち抜き加工時の雰囲気を温度=20±10℃、および相対湿度=30±10%に保ち、かかる環境下で24時間保持することにより、貼付製剤の粘着剤層の水分含量を調節した。
 得られたビソプロロール含有貼付製剤を、PET製フィルム(厚さ=12μm)/アルミニウム箔(厚さ=9μm)/アクリロニトリル系樹脂フィルム(厚さ=30μm)をドライラミネートで積層した包装材により、温度=20±10℃および相対湿度=30±10%の雰囲気下に密封し、ビソプロロール含有貼付製剤の包装体(9cm×9cm)を得た。
[Example 1]
High molecular weight polyisobutylene (viscosity average molecular weight = 4,000,000) 15.1 parts, medium molecular weight polyisobutylene (viscosity average molecular weight = 55,000) 26.1 parts, alicyclic saturated hydrocarbon resin (tackifier) 27 .4 parts, 30.0 parts of isopropyl myristate (organic liquid component) and 1.4 parts of bisoprolol (free form) were mixed with toluene to prepare a viscous toluene solution of the pressure-sensitive adhesive composition. The obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 μm) so that the thickness after drying was 160 μm, and this was applied at 100 ° C. for 5 minutes in a hot air circulating dryer. It dried and the adhesive layer was formed.
This pressure-sensitive adhesive layer is bonded to the nonwoven fabric side of the support, which is a laminated film of a PET film having a thickness of 2 μm and a PET nonwoven fabric (weight per unit area = 12 g / m 2 ), and has a size of 36 cm 2 (6 cm × 6 cm). After punching out, the peripheral part of the patch preparation was pressurized (4.9 MPa) to obtain a bisoprolol-containing patch preparation.
In the manufacturing process of the bisoprolol-containing patch preparation, the atmosphere during the punching process is maintained at a temperature = 20 ± 10 ° C. and a relative humidity = 30 ± 10%, and is kept in such an environment for 24 hours. The moisture content of the layer was adjusted.
The obtained bisoprolol-containing patch preparation was coated with a packaging material in which a PET film (thickness = 12 μm) / aluminum foil (thickness = 9 μm) / acrylonitrile-based resin film (thickness = 30 μm) was laminated by dry lamination, temperature = Sealing was performed under an atmosphere of 20 ± 10 ° C. and relative humidity = 30 ± 10% to obtain a package (9 cm × 9 cm) of a patch preparation containing bisoprolol.
 [実施例2]
 不活性ガス雰囲気下において、アクリル酸2-エチルヘキシル70.0部、ヒドロキシエチルアクリルアミド5.0部、およびN-ビニル-2-ピロリドン25.0部と、重合開始剤としてのアゾビスイソブチロニトリル0.2部を酢酸エチル中、60℃にて溶液重合させてアクリル系粘着剤溶液を調製した。このアクリル系粘着剤溶液65.0部と、有機液状成分としてのミリスチン酸イソプロピル30.0部、およびビソプロロール(フリー体)5.0部を混合し、粘着剤組成物の粘稠酢酸エチル溶液を調製した。得られた溶液を、ポリエチレンテレフタレート(PET)製剥離ライナー(厚さ75μm)上に、乾燥後の厚みが45μmとなるように塗布し、これを熱風循環式乾燥機中で100℃にて5分間乾燥し、粘着剤層を形成した。
 この粘着剤層を、厚さ2μmのPET製フィルムとPET製不織布(目付量=12g/m)との積層フィルムである支持体の不織布側に貼り合わせ、36cm(6cm×6cm)の大きさに打ち抜いてビソプロロール含有貼付製剤を得た。
 ビソプロロール含有貼付製剤の製造工程において、上記打ち抜き加工時の雰囲気を温度=20±10℃、および相対湿度=30±10%に保ち、かかる環境下で24時間保持することにより、貼付製剤の粘着剤層の水分含量を調節した。
 得られたビソプロロール含有貼付製剤を、PET製フィルム(厚さ=12μm)/アルミニウム箔(厚さ=9μm)/アクリロニトリル系樹脂フィルム(厚さ=30μm)をドライラミネートで積層した包装材により、温度=20±10℃および相対湿度=30±10%の雰囲気下に密封し、ビソプロロール含有貼付製剤の包装体(9cm×9cm)を得た。
[Example 2]
Under an inert gas atmosphere, 70.0 parts of 2-ethylhexyl acrylate, 5.0 parts of hydroxyethylacrylamide, and 25.0 parts of N-vinyl-2-pyrrolidone, and azobisisobutyronitrile as a polymerization initiator An acrylic pressure-sensitive adhesive solution was prepared by solution polymerization of 0.2 parts in ethyl acetate at 60 ° C. 65.0 parts of this acrylic pressure-sensitive adhesive solution, 30.0 parts of isopropyl myristate as an organic liquid component, and 5.0 parts of bisoprolol (free body) are mixed, and a viscous ethyl acetate solution of the pressure-sensitive adhesive composition is mixed. Prepared. The obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 μm) so that the thickness after drying was 45 μm, and this was applied in a hot air circulating dryer at 100 ° C. for 5 minutes. It dried and formed the adhesive layer.
This pressure-sensitive adhesive layer is bonded to the nonwoven fabric side of the support, which is a laminated film of a PET film having a thickness of 2 μm and a PET nonwoven fabric (weight per unit area = 12 g / m 2 ), and has a size of 36 cm 2 (6 cm × 6 cm). Then, a bisoprolol-containing patch preparation was obtained.
In the manufacturing process of the bisoprolol-containing patch preparation, the atmosphere during the punching process is maintained at a temperature = 20 ± 10 ° C. and a relative humidity = 30 ± 10%, and is kept in such an environment for 24 hours. The moisture content of the layer was adjusted.
The obtained bisoprolol-containing patch preparation was coated with a packaging material in which a PET film (thickness = 12 μm) / aluminum foil (thickness = 9 μm) / acrylonitrile-based resin film (thickness = 30 μm) was laminated by dry lamination, temperature = Sealing was performed under an atmosphere of 20 ± 10 ° C. and relative humidity = 30 ± 10% to obtain a package (9 cm × 9 cm) of a patch preparation containing bisoprolol.
 [比較例1]
 上記実施例2の貼付製剤の調製に用いたアクリル系粘着剤溶液60.0部と、有機液状成分としての上記ミリスチン酸イソプロピル30.0部と、ポリビニルピロリドン5.0部と、上記ビソプロロール(フリー体)5.0部を混合し、粘着剤組成物の粘稠酢酸エチル溶液を調製した。得られた溶液を、ポリエチレンテレフタレート(PET)製剥離ライナー(厚さ75μm)上に、乾燥後の厚みが45μmとなるように塗布し、これを熱風循環式乾燥機中、100℃にて5分間乾燥して粘着剤層を形成した。この粘着剤層を、厚さ2μmのPET製フィルムとPET製不織布(目付量=12g/m)との積層フィルムである支持体の不織布側に貼り合わせ、36cm(6cm×6cm)の大きさに打ち抜いた後、貼付製剤の周辺部を上記実施例1の場合と同様に加圧してビソプロロール含有貼付製剤を得た。
 得られたビソプロロール含有貼付製剤を、PET製フィルム(厚さ=12μm)/アルミニウム箔(厚さ=9μm)/アクリロニトリル系樹脂フィルム(厚さ=30μm)をドライラミネートで積層した包装材により密封し、ビソプロロール含有貼付製剤の包装体(9cm×9cm)を得た。
 なお、本比較例のビソプロロール含有貼付製剤の製造工程においては、打ち抜き加工時および包装時の貼付製剤の水分含量の調節は行わなかった。
[Comparative Example 1]
60.0 parts of acrylic pressure-sensitive adhesive solution used for the preparation of the patch preparation of Example 2, 30.0 parts of isopropyl myristate as an organic liquid component, 5.0 parts of polyvinylpyrrolidone, and bisoprolol (free) Body) 5.0 parts was mixed to prepare a viscous ethyl acetate solution of the pressure-sensitive adhesive composition. The obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 μm) so that the thickness after drying was 45 μm, and this was applied in a hot-air circulating dryer at 100 ° C. for 5 minutes. It dried and the adhesive layer was formed. This pressure-sensitive adhesive layer is bonded to the nonwoven fabric side of the support, which is a laminated film of a PET film having a thickness of 2 μm and a PET nonwoven fabric (weight per unit area = 12 g / m 2 ), and has a size of 36 cm 2 (6 cm × 6 cm). After punching out, the peripheral part of the patch preparation was pressurized in the same manner as in Example 1 to obtain a bisoprolol-containing patch preparation.
The obtained bisoprolol-containing patch preparation was sealed with a packaging material in which a PET film (thickness = 12 μm) / aluminum foil (thickness = 9 μm) / acrylonitrile resin film (thickness = 30 μm) was laminated by dry lamination, A package (9 cm × 9 cm) of a patch preparation containing bisoprolol was obtained.
In the production process of the bisoprolol-containing patch preparation of this comparative example, the water content of the patch preparation during punching and packaging was not adjusted.
 [比較例2]
 上記実施例2の貼付製剤の調製に用いたアクリル系粘着剤溶液55.0部と、有機液状成分としての上記ミリスチン酸イソプロピル30.0部と、上記ポリビニルピロリドン10.0部と、上記ビソプロロール(フリー体)5.0部を混合し、粘着剤組成物の粘稠酢酸エチル溶液を調製した。得られた溶液を、ポリエチレンテレフタレート(PET)製剥離ライナー(厚さ75μm)上に、乾燥後の厚みが45μmとなるように塗布し、これを熱風循環式乾燥機中、100℃にて5分間乾燥して粘着剤層を形成した。この粘着剤層を、厚さ2μmのPET製フィルムとPET製不織布(目付量=12g/m)との積層フィルムである支持体の不織布側に貼り合わせ、36cm(6cm×6cm)の大きさに打ち抜いた後、貼付製剤の周辺部を上記実施例1の場合と同様に加圧してビソプロロール含有貼付製剤を得た。
 得られたビソプロロール含有貼付製剤を、PET製フィルム(厚さ=12μm)/アルミニウム箔(厚さ=9μm)/アクリロニトリル系樹脂フィルム(厚さ=30μm)をドライラミネートで積層した包装材により密封し、ビソプロロール含有貼付製剤の包装体(9cm×9cm)を得た。
 なお、本比較例のビソプロロール含有貼付製剤の製造工程においては、打ち抜き加工時および包装時の貼付製剤の水分含量の調節は行わなかった。
[Comparative Example 2]
55.0 parts of the acrylic pressure-sensitive adhesive solution used for the preparation of the patch preparation of Example 2, 30.0 parts of the isopropyl myristate as an organic liquid component, 10.0 parts of the polyvinyl pyrrolidone, and the bisoprolol ( Free body) 5.0 parts was mixed to prepare a viscous ethyl acetate solution of the pressure-sensitive adhesive composition. The obtained solution was applied on a polyethylene terephthalate (PET) release liner (thickness 75 μm) so that the thickness after drying was 45 μm, and this was applied in a hot-air circulating dryer at 100 ° C. for 5 minutes. It dried and the adhesive layer was formed. This pressure-sensitive adhesive layer is bonded to the nonwoven fabric side of the support, which is a laminated film of a PET film having a thickness of 2 μm and a PET nonwoven fabric (weight per unit area = 12 g / m 2 ), and has a size of 36 cm 2 (6 cm × 6 cm). After punching out, the peripheral part of the patch preparation was pressurized in the same manner as in Example 1 to obtain a bisoprolol-containing patch preparation.
The obtained bisoprolol-containing patch preparation was sealed with a packaging material in which a PET film (thickness = 12 μm) / aluminum foil (thickness = 9 μm) / acrylonitrile resin film (thickness = 30 μm) was laminated by dry lamination, A package (9 cm × 9 cm) of a patch preparation containing bisoprolol was obtained.
In the production process of the bisoprolol-containing patch preparation of this comparative example, the water content of the patch preparation during punching and packaging was not adjusted.
 [試験例1]粘着剤層の含水率
 温度23±2℃および相対湿度40±5%に制御された環境下で、上記の各実施例および比較例の包装体を開封し、取り出した各ビソプロロール含有貼付製剤をそれぞれ7.5cmに打ち抜いて、試験片を作成した。その後、試験片から剥離ライナーを除去して水分気化装置へ投入した。なお、上記の処理は、包装体の開封から1分以内に完了させた。
 水分気化装置内で試験片を140℃で加熱し、これにより発生した水分を、窒素をキャリヤーとして滴定フラスコへと導入し、カールフィッシャー電量滴定法により、粘着剤層の含水率(粘着剤層の総重量に対する水分の重量の割合(ppm))を測定した。
[Test Example 1] Moisture content of pressure-sensitive adhesive layer Each bisoprolol taken out of the package of each of the above Examples and Comparative Examples in an environment controlled at a temperature of 23 ± 2 ° C and a relative humidity of 40 ± 5% Each of the contained patch preparations was punched out to 7.5 cm 2 to prepare a test piece. Thereafter, the release liner was removed from the test piece and put into a moisture vaporizer. In addition, said process was completed within 1 minute after opening of a package.
The test piece was heated at 140 ° C. in a moisture vaporizer, and the water generated thereby was introduced into the titration flask using nitrogen as a carrier, and the moisture content of the adhesive layer (adhesive layer of the adhesive layer was measured by Karl Fischer coulometric titration). The ratio of the weight of water to the total weight (ppm) was measured.
 [試験例2]ビソプロロールの安定性
 実施例1、2および比較例1、2の包装体を、50±5℃に制御された恒温機内に1ヶ月間保存した。保存前および1ヶ月保存後の貼付製剤より、実施例1の貼付製剤についてはテトラヒドロフラン、実施例2、比較例1および2の貼付製剤についてはメタノールにより抽出し、得られた抽出液を高速液体クロマトグラフィー(HPLC)により分析した。HPLCにおいて検出される、ビソプロロールの分解または変成により生じると推定される類縁物質について、ビソプロロールのピーク面積に対する前記類縁物質の全ピーク面積の面積比を算出し、類縁物質含有量(%)として表した。
(HPLCの測定条件)
 カラム:内径4.6mm、長さ15cmのステンレス管に粒子径が3μmの液体クロマトグラフィー用オクチルシリル化シリカゲルを充填したもの
 カラム温度:40℃
 移動相:
  移動相A(リン酸緩衝液(pH2.5))
  移動相B(リン酸緩衝液(pH2.5)/アセトニトリル=1/4)
 溶出条件:移動相Aおよび移動相Bの混合比を変えて濃度勾配制御する
 流量:1.2mL/分
 検出器:紫外吸光光度計(波長:225nm)
[Test Example 2] Stability of bisoprolol The packaging bodies of Examples 1 and 2 and Comparative Examples 1 and 2 were stored in a thermostat controlled at 50 ± 5 ° C for 1 month. From the patch preparation before storage and after storage for 1 month, the patch preparation of Example 1 was extracted with tetrahydrofuran, the patch preparations of Example 2 and Comparative Examples 1 and 2 were extracted with methanol, and the resulting extract was subjected to high performance liquid chromatography. Analyzed by chromatography (HPLC). For related substances estimated by HPLC to be caused by degradation or modification of bisoprolol, the area ratio of the total peak area of the related substance to the peak area of bisoprolol was calculated and expressed as the content (%) of the related substance. .
(HPLC measurement conditions)
Column: A stainless steel tube having an inner diameter of 4.6 mm and a length of 15 cm packed with octylsilylated silica gel for liquid chromatography having a particle diameter of 3 μm Column temperature: 40 ° C.
Mobile phase:
Mobile phase A (phosphate buffer (pH 2.5))
Mobile phase B (phosphate buffer (pH 2.5) / acetonitrile = 1/4)
Elution conditions: Concentration control is performed by changing the mixing ratio of mobile phase A and mobile phase B Flow rate: 1.2 mL / min Detector: Ultraviolet absorptiometer (wavelength: 225 nm)
 試験例1、2の結果を表1に示した。 Table 1 shows the results of Test Examples 1 and 2.
Figure JPOXMLDOC01-appb-T000001
Figure JPOXMLDOC01-appb-T000001
 表1に示されるように、本発明の実施例1、2の貼付製剤では、粘着剤層の含水率がそれぞれ395ppmおよび6,740ppmであり、試料調製直後の類縁物質含有量は0.5%以下と低く、50℃にて1ヶ月保存後においても、類縁物質含有量は1.0%以下と低い水準に維持されていた。
 これに対して、比較例1、2の貼付製剤では、粘着剤層中の含水率が10,000ppmを超えており、50℃で1ヶ月保存した後には、類縁物質含有量は2.0%以上であり、貼付製剤におけるビソプロロールの安定性が悪いことが示された。
As shown in Table 1, in the patch preparations of Examples 1 and 2 of the present invention, the moisture content of the pressure-sensitive adhesive layer was 395 ppm and 6,740 ppm, respectively, and the content of related substances immediately after sample preparation was 0.5%. The content of related substances was maintained at a low level of 1.0% or less even after storage at 50 ° C. for 1 month.
On the other hand, in the patch preparations of Comparative Examples 1 and 2, the moisture content in the pressure-sensitive adhesive layer exceeds 10,000 ppm, and after storing at 50 ° C. for 1 month, the content of related substances is 2.0%. This is the result, indicating that the stability of bisoprolol in the patch preparation is poor.
 本発明を特定の態様を参照して詳細に説明したが、本発明の精神と範囲を離れることなく様々な変更および修正が可能であることは、当業者にとって明らかである。
 なお、本出願は、2013年9月6日付けで出願された日本特許出願(特願2013-185598)に基づいており、その全体が引用により援用される。
Although the invention has been described in detail with reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention.
This application is based on a Japanese patent application filed on September 6, 2013 (Japanese Patent Application No. 2013-185598), which is incorporated by reference in its entirety.
 本発明によれば、ビソプロロール含有貼付製剤の包装に際し、乾燥剤を使用しなくても、粘着剤層中のビソプロロールの経時的な加水分解が抑制され、経時安定性および信頼性が高められたビソプロロール含有貼付製剤を提供することができる。また、使用性および携帯性に優れるビソプロロール含有貼付製剤の包装体を提供することができる。 According to the present invention, when packaging a bisoprolol-containing patch preparation, bisoprolol in which the time-dependent hydrolysis of bisoprolol in the pressure-sensitive adhesive layer is suppressed without using a desiccant, and stability with time and reliability are improved. A containing patch preparation can be provided. Moreover, the packaging body of the bisoprolol containing medicated patch excellent in usability and portability can be provided.

Claims (8)

  1.  支持体と、その少なくとも片面に形成された、ビソプロロールを含有する粘着剤層とを有し、該粘着剤層の含水率が10,000ppm以下である、ビソプロロール含有貼付製剤。 A bisoprolol-containing patch preparation comprising a support and a pressure-sensitive adhesive layer containing bisoprolol formed on at least one surface thereof, wherein the water content of the pressure-sensitive adhesive layer is 10,000 ppm or less.
  2.  前記粘着剤層の含水率が200ppm~10,000ppmである、請求項1に記載のビソプロロール含有貼付製剤。 2. The bisoprolol-containing patch preparation according to claim 1, wherein the pressure-sensitive adhesive layer has a water content of 200 ppm to 10,000 ppm.
  3.  前記粘着剤層が、アクリル系粘着剤およびゴム系粘着剤からなる群より選択される1種または2種以上の粘着剤を含有する、請求項1または2に記載のビソプロロール含有貼付製剤。 The bisoprolol-containing patch preparation according to claim 1 or 2, wherein the pressure-sensitive adhesive layer contains one or more pressure-sensitive adhesives selected from the group consisting of an acrylic pressure-sensitive adhesive and a rubber-based pressure-sensitive adhesive.
  4.  さらに、前記粘着剤層の粘着面に仮着された剥離ライナーを備える、請求項1~3のいずれか1項に記載のビソプロロール含有貼付製剤。 The bisoprolol-containing patch preparation according to any one of claims 1 to 3, further comprising a release liner temporarily attached to the adhesive surface of the adhesive layer.
  5.  請求項1~4のいずれか1項に記載のビソプロロール含有貼付製剤が、耐透湿性袋体中に封入されている、ビソプロロール含有貼付製剤の包装体。 A package of bisoprolol-containing patch preparation, wherein the bisoprolol-containing patch preparation according to any one of claims 1 to 4 is encapsulated in a moisture-permeable bag.
  6.  前記耐透湿性袋体が、アクリロニトリル系樹脂層と、水分不透過性層とが積層されてなる包装材を、該アクリロニトリル系樹脂層が、前記ビソプロロール含有貼付製剤の近位側に位置するように密封したものである、請求項5に記載の包装体。 The moisture-permeable bag is a packaging material in which an acrylonitrile resin layer and a moisture impermeable layer are laminated so that the acrylonitrile resin layer is located on the proximal side of the bisoprolol-containing patch preparation. The package according to claim 5, which is sealed.
  7.  前記耐透湿性袋体内に乾燥剤が封入されていない、請求項5または6に記載の包装体。 The package according to claim 5 or 6, wherein a desiccant is not enclosed in the moisture-permeable bag.
  8.  前記耐透湿性袋体が、乾燥剤を含有しない包装材により形成されている、請求項5~7のいずれか1項に記載の包装体。 The packaging body according to any one of claims 5 to 7, wherein the moisture-permeable bag body is formed of a packaging material containing no desiccant.
PCT/JP2014/073505 2013-09-06 2014-09-05 Bisoprolol-containing adhesive patch and package of same WO2015034051A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201480048897.3A CN105517543A (en) 2013-09-06 2014-09-05 Bisoprolol-containing adhesive patch and package of same
KR1020167005441A KR20160049532A (en) 2013-09-06 2014-09-05 Bisoprolol-containing adhesive patch and package of same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013-185598 2013-09-06
JP2013185598A JP2015051947A (en) 2013-09-06 2013-09-06 Bisoprolol-containing patch formulation and packed body thereof

Publications (1)

Publication Number Publication Date
WO2015034051A1 true WO2015034051A1 (en) 2015-03-12

Family

ID=52628512

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/073505 WO2015034051A1 (en) 2013-09-06 2014-09-05 Bisoprolol-containing adhesive patch and package of same

Country Status (5)

Country Link
JP (1) JP2015051947A (en)
KR (1) KR20160049532A (en)
CN (1) CN105517543A (en)
TW (1) TW201542251A (en)
WO (1) WO2015034051A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6654365B2 (en) * 2015-06-17 2020-02-26 日東電工株式会社 Patch preparation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505342A (en) * 1994-08-27 1998-05-26 エルティーエス ローマン テラピイー システム ゲーエムベーハー Transdermal therapeutic system with protection against hydrolysis
WO2005072716A1 (en) * 2004-01-30 2005-08-11 Hisamitsu Pharmaceutical Co., Inc. Plaster enclosing packaging bag
JP2007099759A (en) * 2005-09-09 2007-04-19 Nitto Denko Corp Adhesive preparation containing bisoprolol

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2368652T3 (en) * 2005-09-09 2011-11-21 Nitto Denko Corporation ADHESIVE PREPARATION CONTAINING BISOPROLOL.
KR20090118957A (en) * 2007-03-08 2009-11-18 닛토덴코 가부시키가이샤 Device for the transdermal administration of bisoprolol
US20110056863A1 (en) * 2008-05-30 2011-03-10 Junichi Sekiya Adhesive preparation containing donepezil, and package of the same
JP5776079B2 (en) * 2010-02-26 2015-09-09 日東電工株式会社 Patch preparation containing bisoprolol

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10505342A (en) * 1994-08-27 1998-05-26 エルティーエス ローマン テラピイー システム ゲーエムベーハー Transdermal therapeutic system with protection against hydrolysis
WO2005072716A1 (en) * 2004-01-30 2005-08-11 Hisamitsu Pharmaceutical Co., Inc. Plaster enclosing packaging bag
JP2007099759A (en) * 2005-09-09 2007-04-19 Nitto Denko Corp Adhesive preparation containing bisoprolol

Also Published As

Publication number Publication date
KR20160049532A (en) 2016-05-09
JP2015051947A (en) 2015-03-19
TW201542251A (en) 2015-11-16
CN105517543A (en) 2016-04-20

Similar Documents

Publication Publication Date Title
JP5870350B2 (en) Bisoprolol transdermal administration device
JP2007099759A (en) Adhesive preparation containing bisoprolol
WO2010134433A1 (en) Transdermal preparation
CA2845165C (en) Composition for enhancing transdermal absorption of drug and patch preparation
JP6349170B2 (en) Patches and patch preparations
JP6569045B2 (en) Patch preparation containing bisoprolol and its package
WO2015034051A1 (en) Bisoprolol-containing adhesive patch and package of same
JP2012158612A (en) Adhesive preparation containing bisoprolol
JP5930877B2 (en) Transdermal absorption preparation
WO2015034054A1 (en) Bisoprolol-containing patch preparation
JP2013132367A (en) Patch preparation
JP6318356B2 (en) Patch preparation containing bisoprolol and its package
JP6318355B2 (en) Patch preparation containing bisoprolol
JPH06211696A (en) Percutaneous absorption pharmaceutical preparation of eperisone or tolperisone
JP2018177758A (en) Rivastigmine-containing percutaneously absorbable pharmaceutical preparation
JP2019038794A (en) Rivastigmine percutaneous absorption type patch formulation
JPH1149669A (en) Antiviral agent-containing tape preparation
JP2015051949A (en) Patch preparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14841472

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 20167005441

Country of ref document: KR

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14841472

Country of ref document: EP

Kind code of ref document: A1